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Abstract 
Inadequately controlled acute pain is a problem for hospitalized patients.  Non-pharmacological 
pain management interventions (NPPMIs) are recommended but underutilized.  Nurse-directed 
lavender aromatherapy is a feasible and effective NPPMI.  Patients at a community hospital, 
including its surgical-orthopedic unit, reported lower patient pain management experience scores 
than the average score of Magnet Recognition status hospitals.  The community hospital planned 
to improve pain management by implementing nurse-directed lavender aromatherapy.  The 
purpose of this evidence-based practice project was to fortify the hospital’s nurse-directed 
lavender aromatherapy implementation with change agents.  A logic model guided 
implementation.  Project aims were to increase the surgical-orthopedic unit’s pain management 
experience scores and to offer nurse-directed lavender aromatherapy to all appropriate patients 
by close of the project.  Change agents included a Doctor of Nursing Practice student and nurse 
pain champions.  Interventions included Doctor of Nursing Practice student-led: (a) surgical-
orthopedic unit Lunch & Learn presentations and Rounding for Results sessions and (b) 
implementation discussions with nurse pain champions from four units, including the surgical-
orthopedic unit.  Because of these interventions, surgical-orthopedic unit patient pain experience 
scores increased from 43rd percentile to 78th percentile.  In five of six project weeks, all 
appropriate surgical-orthopedic unit patients were offered nurse-directed lavender aromatherapy.  
Adoption of the practice change was successful, but slower than anticipated because of slow 
adoption by the nurses.  Nurse leaders responded to this slow adoption by adding additional 
change agent rounds.  Logic model development and change agents are effective strategies for 
NPPMI implementation.  
CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 6 
 
Change Agent Impact on Pain Management Experience through Lavender Aromatherapy: 
Evidence-Based Practice Project 
Introduction 
Patients experiencing acute pain, particularly post-operative pain, often report it is 
inadequately controlled (Chou et al., 2016).  Provision of non-pharmacological pain management 
interventions (NPPMIs) is a recommendation in evidence-based clinical practice guidelines 
(CPGs) (Chou et al., 2016; Mack et al., 2014; Registered Nurses’ Association of Ontario 
[RNAO], 2013).  A recent Joint Commission notice advised that NPPMIs are a critical element 
for effective pain management (Joint Commission, 2018).  Aromatherapy with direct lavender 
inhalation has been associated with patient report of decrease in pain intensity in patients with 
acute and chronic pain, particularly post-operative pain (Bagheri-Nesami, Espahbodi, Nikkhah, 
Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; Johnson et al., 
2016; Karaman et al., 2016; Kim et al., 2007; Lakhan, Sheafer, & Tepper, 2016).  
Clinical aromatherapy is the topical application or inhalation of an essential oil to assist 
patients in managing symptoms such as pain, nausea, or anxiety (Buckle, 2015).  Aromatic oils 
were used in ancient China, Egypt, India, and Greece, where the physician Hippocrates 
advocated aromatic baths and massages (Alliance of International Aromatherapists, n.d.).  The 
term aromatherapy was created in 1937 by a chemist in France, René-Maurice Gattefossé 
(Buckle, 2015).  In that same time-period, nurse and biochemist Marguerite Maury provided 
community education about the use aromatherapy to enhance wellness (Buckle, 2015). 
Interventions such as aromatherapy require implementation science approaches, such as 
the Iowa model of evidence-based practice (EBP), to optimize adoption and sustainment (Cullen 
& Adams, 2012).  Change agents are identified as an implementation strategy in the Iowa model 
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including unit-based champions, local opinion leaders, and external experts (Cullen et al., 2018).  
The purpose of this EBP project was to employ internal and external change agents to fortify 
implementation of lavender aromatherapy to improve patient pain management experience in a 
community hospital.  The change agents for this project included a Doctor of Nursing Practice 
(DNP) student and four unit-based nurse pain champions (PCs). 
Background and Significance 
Needs Assessment 
The 216-bed community hospital for this study resided in a 10-hospital system in the 
Mid-Atlantic United States.  This community hospital resides in a suburban region near a major 
East Coast city and became a member of the health system in December 2012 ("Hospital 
merger," 2012). 
Pain management for patients has been a focus for this health system since fiscal year 
(FY) 2014, when it endorsed the Assessment and Management of Acute Pain in the Hospitalized 
Adult Nursing CPG (2014) as the standard of practice (Mack et al., 2014).  This CPG was 
adapted from a guideline developed by the Registered Nurses Association of Ontario (2013) in 
consultation with a nationally known nurse pain expert.  The recommendations pertinent to 
NPPMIs are:  
• “Psychological (psychosocial) interventions such as cognitive behavior therapy, 
music, distraction, relaxation techniques, and education should be considered in pain 
management because these interventions affect the way a person thinks, feels, and 
responds to pain” (Mack et al., 2014, p. 10). 
• “Physical interventions such as physiotherapy and exercise, massage, positioning, and 
application of heat or cold should be considered along with pharmacological 
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interventions to reduce pain, improve sleep, mood and general wellbeing. When using 
more specialized interventions (TENS, acupuncture) consult the appropriate 
interprofessional team” (Mack et al., 2014, p. 10). 
• “Evaluate any non-pharmacological (physical and psychological) interventions for 
effectiveness and the potential for interactions with pharmacological interventions 
(Ib)” (Mack et al., 2014, p. 10). 
•  “Reassess the person’s response to the pain management interventions consistently 
using the same re-evaluation tool…The intensity of monitoring (frequency and 
duration) depends on a person’s risk profile for opioid-induced sedation and 
respiration depression and the onset and duration of action or potential adverse effects 
of the pharmacologic and non-pharmacologic interventions” (Mack et al., 2014, p. 
10-11). 
In FY 2016, key pain management stakeholders from the health system endorsed the 
recommendations in the American Pain Society postoperative pain management CPG (Chou et 
al., 2016).  The authors recommended NPPMIs such as transcutaneous electrical nerve 
stimulation (TENs) and cognitive-behavioral therapies, including relaxation therapies.  
Aromatherapy is an intervention that promotes relaxation in patients with pain but is not 
specifically included in the list of relaxation therapies in either CPG (Czarnecki & Turner, 2018). 
In September 2016, the health system’s Nursing Practice Council (NPC) completed an 
audit of 65 open medical records from 10 hospitals to evaluate documentation of delivery of key 
recommendations in the Assessment and Management of Acute Pain in the Hospitalized Adult 
Nursing CPG (Mack et al., 2014).  The audit included an assessment of the documentation of 
presence and type of NPPMIs provided to patients not achieving an acceptable pain goal.  In the 
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audited patients, less than 32% of those with unmet pain goals had received a NPPMI (Appendix 
A).  A total of 21 NPPMIs were documented; some patient records recorded more than one 
intervention.  Of the 21 NPPMIs noted, repositioning was documented in nine records, 
application of cold was documented in two records, and provision of quiet environment was 
documented in two records.  Application of heat, assistance with activities of daily living, 
comfort measures, distraction, education, relaxation, pressure relief, reduced stimuli, and 
relaxation techniques were each documented in one record.  The NPC advised that additional 
NPPMIs for patients were needed and should be selected based on efficacy and feasibility for 
nursing practice.  
The need for additional NPPMIs was validated by observations on bedside pain CPG 
rounds at each of the 10 hospitals in the health system by the advanced practice registered nurse 
(APRN) responsible for oversight of the CPG.  Two nurses with expertise in pain management 
from outside of the health system were consulted regarding potential NPPMIs.  These nurses 
identified aromatherapy as a feasible and effective intervention for clinical nurses to provide to 
hospitalized patients to help manage pain (D. Chapa, personal communication, September 8, 
2016; T. Dintzner, personal communication, September 23, 2016).  Subsequently, a systematic 
review of lavender aromatherapy for acute pain management in adults, defined as those ages 18 
and older, was completed in December 2016 by the APRN (Mack & Zhou, 2016).  Lavender 
essential oil was selected because it was: (a) the most frequently identified effective essential oil 
used in the acute pain randomized controlled trials identified in the systematic review and (b) 
one of the most effective scents identified in an aromatherapy observational study at a mid-west 
health system (Mack & Zhou, 2016; Johnson et al., 2016).  In February 2017, the nurse pain 
expert consulted in 2014 returned to the health system to provide educational sessions and 
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hospital site visits to evaluate the CPG implementation (Gordon, 2017).  Based on observations 
during these site visits, the nurse pain expert validated the need to increase the NPPMI options 
for nurses to provide to patients. 
In August 2017, an advisory team of the health system’s Nursing Leadership 
Development Program presented a system-level plan to fully implement the Assessment and 
Management of Acute Pain in the Hospitalized Adult Nursing CPG.  Implementation of 
aromatherapy for pain management was among the recommendations in the plan. 
In October 2017, the health system APRN attended the “How to Launch an 
Aromatherapy Program within a Hospital or Health System” course presented by the Penny 
George Institute for Health and Healing at Allina Health in Minnesota to develop a nurse-
directed lavender aromatherapy pain management protocol and system implementation plan 
(Streeter, 2017).  In November 2017, the health system held a Pain Summit at which a clinical 
nurse presented education about aromatherapy for pain management (Ryan, 2017).  
Development of a product trial of lavender aromatherapy for pain management and associated 
deliverables was begun in December 2017 and completed in August 2018 (Appendix B).  Project 
plan steps included:   
• Obtaining approval for the product by Nursing Product Evaluation and Standardization 
Council (NPESC) in collaboration with the health system supply chain team.  NPESC 
required a product trial, including clinical nurses’ evaluation of the lavender inhalers, 
prior to final approval for patient use in all hospitals in the health system.  In January 
2018, the supply chain team located several lavender aromatherapy products to evaluate 
that met safety criteria described by the Penny George Institute aromatherapist (Streeter, 
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2017).  The NPESC approved one of the lavender products that was an inhaler for the 
trial.  
• Development of a clinical protocol (Appendix C).  The clinical protocol was vetted with 
health system physician subject matter experts: an allergist, a pulmonologist specializing 
in asthma management, and an anesthesiologist.  Additional input included health system 
leaders from occupational health (which manages the health of employees) and laundry 
services (which could be impacted by aromatherapy products being inadvertently mixed 
with the linens) who jointly advised that the lavender inhaler was an acceptable product.  
• Creation of a patient and family education lavender aromatherapy document by the NPC 
with consultation by a health literacy expert and endorsed by the Patient and Family 
Education Council (Appendix D). 
• Development of nursing education on lavender aromatherapy for the product trial and 
endorsement for system-wide use after the trial by the Nursing Professional Development 
Excellence Committee (Appendices E and F). 
• Development of nursing documentation for the nurse-directed aromatherapy protocol 
within the electronic medical records (EMR) system that is used in nine of the 10 health 
system hospitals.  This included: (a) a clinical decision support process to assist nurses to 
determine the appropriateness of lavender aromatherapy, (b) prompts to document pain 
intensity after the first administration, and (c) fields for documentation of initial and 
ongoing inhaler use (see screenshots in Appendix E). 
• Development of a physician communication brief highlighting key research that was 
vetted with physician leaders at the pilot hospitals and disseminated as part of the pilot 
(Appendix G). 
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The pilot was completed at two hospitals in August 2018 and resulted in the NPESC 
endorsement of the lavender Aethereo®Sticks inhaler product for system-wide implementation in 
September 2018.  No adverse events were noted in patients, visitors, nurses, physicians, or other 
hospital associates during the trial.  The community hospital for this study was not a pilot site.  A 
launch brief containing product cost and ordering information was issued by the system supply 
chain team in November 2018 (Appendix H).  
Among the 10 hospitals in the health system, the study community hospital was selected 
as the focus for this project, because it had not met the health system pain management patient 
experience target score of the Magnet hospital average in over 12 months.  The community 
hospital scored at the 33rd percentile in the prior 12 months.  In the first quarter of fiscal year 
2019, the community hospital scored in the 31st percentile as compared to NRC database Magnet 
hospitals.  The NRC database analysis indicated pain management was one of the key drivers of 
patients’ overall rating of the community hospital on a zero to 10 scale.  The surgical-orthopedic 
unit scores were in the lower half of study hospital’s units’ scores, scoring at the 30th percentile 
over the prior 12 months and in the 12th percentile for the first quarter of FY 2019. 
Annual observational visits beginning in 2016 conducted by the health system’s APRN 
responsible for pain management and the nurse pain expert visit in 2017 validated the 
community hospital’s patients were not receiving cognitive NPPMIs.  Due to the need for 
cognitive NPPMI to improve patients’ pain management experience, implementation of nurse-
directed lavender aromatherapy was an organizational priority supported by the community 
hospital’s Chief Nursing Officer (CNO) and Vice-President for Medical Affairs. 
Each hospital in the health system, including the community hospital for this study, 
convened a multidisciplinary committee, including the hospital supply chain team, to implement 
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the aromatherapy protocol with lavender inhalers.  The community hospital’s plan was impacted 
by the transition to the health system’s EMR system on November 29, 2018.  This EMR system 
included the documentation fields and decision support necessary for implementation of 
aromatherapy.  To allow clinicians time to adapt to the new system, the community hospital’s 
implementation team determined aromatherapy implementation would commence in the first 
quarter of FY 2019.  
During this time-period, a system-wide nurse PC program began on October 31, 2018 
with training for groups of nurse leaders and clinical nurses from all 10 hospitals.  Clinical 
nurses from all inpatient units were appointed by nurse leaders to be nurse PCs.  The program 
required each nurse PC to attend at least 75% of monthly meetings.  The community hospital 
held its first PC meeting in the first quarter of FY 2019, on January 23, 2019.  
In addition to the aromatherapy protocol that all system hospitals employed, the 
community hospital’s implementation was fortified by this EBP project that included: (a) 
engaging the hospital’s newly appointed nurse PCs through DNP student-facilitated meeting 
discussions regarding how to promote aromatherapy use and (b) providing DNP Student-led 
Lunch & Learn presentations and Rounding for Results sessions on the surgical-orthopedic unit 
to promote aromatherapy use.   
Goals of this intervention were: (a) for the community hospital’s surgical-orthopedic unit 
to meet or exceed the Hospital Consumer Assessment of Healthcare Providers and Systems 
(HCAHPS) average score for Magnet hospitals based on raw, unadjusted scores in the NRC 
Picker database target for pain management patient experience at all hospitals and (b) for all 
appropriate surgical-orthopedic unit patients to receive an offer of lavender aromatherapy as an 
option to help manage pain. 
CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 14 
 
The surgical-orthopedic unit was selected for the Lunch & Learn presentations and 
Rounding for Results sessions because its patients were more likely to have acute pain, with or 
without chronic pain, than patients in non-surgical units, who were more likely to have only 
chronic pain.  Surgical-orthopedic patients commonly experienced both acute pain from 
operative procedures and chronic pain from osteoarthritis in non-operative joints (Doi, Shimoda, 
& Gibbons, 2014).  Aromatherapy has been associated with positive effect for both acute and 
chronic pain, but the magnitude of effect is greater with acute pain (Lakhan, Sheafer, & Tepper, 
2016).  Therefore, aromatherapy was likely to benefit the pain experience of patients on this unit 
to a greater magnitude than those on non-surgical units. 
Problem Statement 
Most post-operative patients report unsatisfactory pain management that can limit 
surgical recovery and result in deconditioning, hypercoagulability, respiratory compromise, 
decreased bowel motility, and chronic pain (Chou et al., 2016).  NPPMIs are recommended in 
addition to multimodal analgesic medications in consensus guidelines to improve pain 
management and decrease reliance on opioids (Chou et al., 2016; Kim et al., 2007; Mack et al., 
2014; RNAO, 2013).  Opioid medication risks include constipation, opioid-induced sedation, 
respiratory depression, and even death (Czarnecki & Turner, 2018).  
Use of aromatherapy with lavender essential oil is a NPPMI (Buckle, 2015).  Clinical 
research studies of lavender aromatherapy have demonstrated improvement in pain intensity, 
patient satisfaction with pain management, and decreased utilization of opioid medication 
(Bagheri-Nesami, Espahbodi, Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; 
Irmak Sapmaz et al., 2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2007; Kim et 
al., 2006; Lakhan et al., 2016).  
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Clinical observations and documentation audits of patient pain management at the health 
system, including the study community hospital, demonstrated that NPPMIs were not routinely 
provided to patients with pain (Appendix A).  In those patients who received NPPMIs, body 
positioning to decrease pain was the most frequently documented and observed intervention.  
This prompted a dialogue with clinical experts and subsequent literature review of lavender 
aromatherapy that resulted in the selection of lavender aromatherapy as a new NPPMI for all 
health system hospitals.  
This practice change, the initiation of nurse-directed aromatherapy, required the 
implementation science approach of the Iowa model of EBP to optimize adoption and 
sustainment (Cullen & Adams, 2012; Cullen et al., 2018).  The focus of this EBP project was to 
improve pain management at the community hospital through fortifying the practice change of 
aromatherapy by engaging change agents, an Iowa model implementation strategy, including: a 
DNP student who provided Lunch & Learn presentations and Rounding for Results sessions on 
the surgical-orthopedic unit and four nurse PCs who promoted use of lavender aromatherapy on 
their units.  
Use of the Iowa model strategy of change agents to guide lavender aromatherapy 
implementation for post-operative patients resulted in improved HCAHPS pain management 
scores.  DNP student-led unit-based Lunch & Learn presentations (Appendix I), DNP student-
facilitated nurse PC meeting discussions regarding how to promote aromatherapy use (Appendix 
J), and computer-based module completion (Appendix E) promoted the practice change of nurse-
directed lavender aromatherapy for pain management by creating interest and awareness and 
building knowledge and commitment.  DNP student-led Rounding for Results sessions promoted 
action and adoption of the lavender aromatherapy (Appendix K).  Ongoing nurse PC meetings 
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and activities were identified as a method to pursue integration and sustainment through peer 
coaching and sharing of implementation outcome data with peers.  Lavender aromatherapy EMR 
reports and monthly reports of inhaler usage provided by the hospital supply chain team were 
utilized to measure adoption of the practice change of nurse-directed lavender aromatherapy. 
The project implemented and evaluated an Iowa model-guided initiative to fortify the 
community hospital’s implementation of nurse-directed lavender aromatherapy for pain 
management, through DNP student and nurse PC change agents.  
Purpose Statement 
The purpose of this EBP project was to employ change agents (an Iowa model EBP 
dissemination strategy) to fortify implementation of nurse-directed lavender aromatherapy for 
patient pain management in a community hospital.  
Practice Question 
The primary clinical question for this project was: 
Was the strategy of change agents effective in achieving implementation of nurse-
directed lavender aromatherapy to improve pain management experience in adult patients 
on a surgical-orthopedic unit of a community hospital? 
Aims and Objectives 
Aim  
To increase the surgical-orthopedic unit patient HCAHPS pain management experience 
score to equal or above the Magnet average of hospitals in the NRC Picker database and to 
achieve a consistent practice of 100 % of appropriate patients being offered lavender 
aromatherapy by the end of the third quarter of FY 2019.  
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Objectives 
• To build knowledge and commitment of clinical nurses regarding implementation of 
NPPMIs, particularly lavender aromatherapy. 
• To engage nurse PCs to promote action and adoption of lavender aromatherapy for pain 
management.  
• To promote integration and sustained use of lavender aromatherapy, through evaluation 
of HCAHPS pain experiences scores, lavender inhaler consumption reports, and EMR 
aromatherapy documentation reports. 
Review of the Literature 
Aromatherapy for Pain Management 
A database search including PubMed and CINAHL using search terms of aromatherapy 
and pain and pain management was conducted with the help of a research librarian.  The search 
inclusion criteria were: the population must include adults cared for in a medical-surgical unit or 
procedural/surgical area, the intervention must include aromatherapy with lavender, the outcome 
of self-reported pain must be reported, the study must have an experimental design and control, 
peer-reviewed journal publication, English language, and publication years of 2006 through 
2016.  
Six randomized controlled trials of lavender essential oil inhalation for acute pain were 
identified.  All were conducted in an academic university or medical centers in three locations: 
two studies conducted in Iran, two in Turkey, and two in New York city (Bagheri-Nesami et al., 
2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; Karaman et al., 2016; Kim et al., 
2007; Kim et al., 2006) (Appendix L).  Patient populations in five of these studies were selected 
because they were undergoing procedures that are typical of the hospital setting and produce 
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acute pain including: hemodialysis access cannulation, peripheral venous cannulation, cardiac 
surgery with sternotomy, gastric banding, and breast biopsy.  The remaining study focused on 
the diagnosis of renal colic that is a medical diagnosis associated with acute pain.  Aromatherapy 
with lavender inhalation was noted to have a significant effect on the outcome of self-reported 
acute pain as compared to placebo in five of the six studies with reported p values ranging from 
< .001 to < .05 (Bagheri-Nesami et al., 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 
2015; Karaman et al., 2016; Kim et al., 2007).  Kim and colleagues’ (2006) initial study of 
patients undergoing breast biopsy did not note a significant difference in pain intensity between 
those who received placebo and those who received lavender aromatherapy, but both groups 
reported low levels of pain intensity.  Reduction in opioid use was observed in one study (Kim et 
al., 2007). 
In addition, a meta-analysis and a large observational study fortified the evidence for 
aromatherapy for pain (Johnson et al., 2016; Lakhan, Sheafer, & Tepper, 2016).  A systematic 
review and meta-analysis of pooled data from twelve randomized controlled trials in which 
aromatherapy was an intervention for acute or chronic pain concluded that there was a 
statistically significant reduction in pain intensity and a large effect size (Lakhan, Sheafer, & 
Tepper, 2016).  The meta-analysis demonstrated a larger magnitude of effect for acute pain than 
chronic pain.  A large observational trial of over 5,000 administrations of lavender essential oil 
in a hospital system in the mid-western United States noted a mean reduction in pain intensity of 
three points on an 11-point scale and no associated serious safety events (Johnson et al., 2016).  
The National Institutes of Health National Center for Complementary and Integrative 
Health (2016) provided the opinion that current aromatherapy research includes only studies of 
insufficient size and quality to warrant a recommendation of effectiveness of its use for symptom 
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relief, including pain management.  This contrasts with the findings of the meta-analysis, 
randomized controlled trials, and observational study (Bagheri-Nesami et al., 2014; Heidari Gorji 
et al., 2015; Irmak Sapmaz et al., 2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 
2007; Lakhan et al., 2016).  
Change Agents 
Database queries including OVID® Medline, CINAHL, SCOPUS, and Clinical Key for 
Nursing using search terms of “Pain Champion” and “Pain Resource Nurse” were conducted.  
These terms are used interchangeably in the literature.  The search inclusion criteria were: peer-
reviewed journal publications, English language, and no limit on publication years.  A search of 
Pain Management Nursing journal from 2007 to present using the search term “Pain Resource 
Nurse” was also conducted.  Hand searches of articles and the references in the chapter on 
implementation by Cullen and colleagues (2018) were performed.  Articles were organized by 
hierarchy of evidence and scanned content that included nurse PC program evaluations or the 
role of APRN pain champions, since the DNP student in this project was an APRN. 
The only randomized controlled trial of the effectiveness implementation of a nurse PC 
program, took place in a 650-bed university-affiliated hospital in Iceland (Gunnarsdottir et al., 
2017).  Twelve adult medical-surgical units were randomized to initial program implementation 
and eleven units served as the control, with a plan to implement the program on those units in the 
future.  A three-day training nurse PC course was provided to 24 nurses.  The course was 
followed by a six-month process in which each nurse PC was mentored by a clinical nurse 
specialist (CNS).  Clinical outcomes were measured before and after implementation with: (a) 
pain management index that evaluated pain with both pain intensity and the strength of 
analgesics a patient received and (b) a standardized pain questionnaire (Cleeland et al., 1994; 
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Gordon et al., 2010).  Two nursing outcomes were measured pre and post implementation: (a) 
nurses’ selection of an appropriate pain assessment tool, based on medical records 
documentation review and (b) a standardized knowledge and attitudes survey provided to all 
nurses in the hospital (Ferrell & McCaffery, 2014).  No significant differences were found in 
patient pain intensity, patient pain experience, or nursing knowledge and attitudes regarding pain 
management.  Significant improvement in nurses’ selection of appropriate pain assessment tools 
was noted.  The study was well designed because: (a) control nursing units were measured in 
comparison with units with nurse PCs, (b) the number of nursing units included was adequate for 
statistical power, and (c) both patient and nursing outcomes were measured.  There were a 
number of limitations including: (a) the intervention focused on improving nursing knowledge, 
but there was no assessment of the quality of the multidisciplinary practice environment that is 
essential for pain management; (b) the pre and post assessment interval was six-months, despite 
the authors’ acknowledgement that transition to the nurse PC role often requires a year or more; 
(c) the authors asserted that informing the leadership of the program ensured support, but did not 
measure the degree of leadership support nurses experienced; and (d) a lack of process or 
effectiveness measures for the mentorship phase.   
Thirteen descriptive, qualitative and mixed methods pain champion program evaluations 
identified challenges, facilitators, and benefits.  Challenges included: (a) sustaining leadership 
support, (b) time for nurse PCs to attend meetings, (c) incorporating the role during the workday, 
(d) visibility to peers, (e) receptiveness of nurse colleagues, (f) the slow pace of practice change, 
and (g) a focus on regulatory outcomes over patient outcomes (Allen et al., 2018; Ferrell, Grant, 
Ritchie, Ropchan, & Rivera, 1993; Ladak et al., 2013; McCleary, Ellis, & Rowley, 2004; Tong et 
al., 2019). Facilitators included: (a) initial didactic education on pain management and the pain 
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champion role, (b) nursing unit leadership support, (c) dedicated time for meetings and activities, 
(d) clear role expectations, (e) clinical mentors, and (f) dedicated acute pain provider teams 
(Ladak et al., 2013; McCleary, Ellis, & Rowley, 2004; Overstreet, 2012; Tong et al., 2019). 
Benefits included: (a) improved and sustained nursing knowledge, (b) sustained confidence in 
pain management, (c) improved documentation of pain assessment, (d) adoption of pain 
management practice changes, (e) improved patient pain experience, (f) decreased pain 
prevalence, and (g) improved patient and clinician communication about pain management  
(Allen et al., 2018; Eaton, Gordon, & Doorenbos, 2013; Ferrell et al., 1993; Grant, Ferrell, 
Hanson, Sun, & Uman, 2011; Greenway & Corston, 2016; Holley, McMillan, Hagan, Palacios, 
& Rosenberg, 2005; Ladak et al., 2013; McCleary, Ellis, & Rowley, 2004; McMillan, Tittle, 
Hagan, & Small, 2005; Overstreet, 2012; Paice, Barnard, Creamer, & Omerod, 2006; Telford, 
Nichols, & Watson, 2019; Tong et al., 2019). 
The role of the APRN as a pain champion included: (a) patient assessment and care 
planning; (b) education of nurses and other clinicians; (c) developing a culture of trust with and 
among clinical nurses and other disciplines; and (d) protocol implementation including 
assessment of barriers, practice reminders, medical record audits (Kaasalainen et al., 2015; 
McCleary et al., 2004).  Barriers in APRN implementation of protocols included: less APRN 
time at the bedside than clinical nurses, competition of EBP protocols with other change 
initiatives, clinical nurse resistance to change, and turnover in clinical nurses (Kaasalainen et al., 
2015; McCleary et al., 2004).  Facilitators in APRN implementation of protocols included: (a) a 
dedicated APRN pain champion was responsible for protocol oversight, (b) senior leadership 
supported the APRN role in protocol implementation, (c) an APRN provided education and 
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mentoring of clinical nurses regarding the protocol, and (d) an APRN applied advanced 
knowledge of pain medications to care planning (Kaasalainen et al., 2015). 
Theoretical Framework 
The Iowa Model of EBP Implementation  
Implementation of evidence to practice at the health system was informed by the Iowa 
model of EBP for: (a) identification of the practice improvement opportunity, (b) evaluation and 
synthesis of evidence, and (c) evidence-based dissemination strategies (Cullen & Adams, 2012; 
Cullen et al., 2018).  The Iowa model process for identification of the practice improvement 
opportunity, review of the literature, and synthesis of evidence was completed prior to the health 
system lavender aromatherapy pilot.  Evidence for the use of NPPMIs was based on CPG 
evidence-based recommendations (Chou et al., 2016; Mack et al., 2014).  A literature review of 
aromatherapy, a NPPMI that is feasible nurse-directed implementation, provided additional 
evidence (Bagheri-Nesami et al., 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; 
Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2007; Lakhan et al., 2016).  
The Iowa model provided a table of evidence-based implementation strategies across four 
phases and two areas of focus for this EBP project, which is shown in Appendix M.  The phases 
were: (a) create interest and awareness, (b) build knowledge and commitment, (c) promote action 
and adoption, and (d) purse integration and sustained use.  The areas of focus were: (a) 
connecting with clinicians, organizational leaders, and key stakeholders; and (b) building 
organizational support. 




In addition to appraisal and synthesis of evidence, this EBP implementation required an 
assessment of the context of practice and the necessary resources, stakeholders, and processes to 
achieve the desired patient outcomes (Melnyk & Fineout-Overholt, 2011; Millar, Simeone, & 
Carnevale, 2001).  A logic model was selected as the program planning tool (McCawley, 2001).  
The logic model was used to: (a) identify the priorities to be addressed in the project; (b) 
compare the state of clinical care prior to the project to the desired outcomes; (c) identify inputs 
and outputs needed to achieve these outcomes; and (d) identify assumptions and external factors 
that may impact the success of the project (McCawley, 2001; Millar et al., 2001). Project 
outcomes were segmented into three temporal types: short-term, medium-term, and long-term 
(McCawley, 2001; Millar et al., 2001; Taylor-Powell, Jones, & Henert, 2003).  
The logic model outcomes aligned with the four dissemination phases of the Iowa model: 
(a) short-term outcomes included creation of interest and awareness of the need for the desired 
practice and knowledge and commitment required for the practice change, (b) medium-term 
outcomes included the action and adoption of the practice change, and (c) long-term outcomes 
included the integration and sustainment of the practice change and its impact on the identified 
need (Cullen et al., 2018; McCawley, 2001; Taylor-Powell et al., 2003) (Appendix N). 
Situation. 
Adult patients, ages 18 and older, in the community hospital rated their pain management 
experience during hospitalization with the Hospital Consumer Assessment of Healthcare 
Providers and Systems (HCAHPS) survey.  The health system HCAHPS pain experience score 
target for all hospitals, including the community hospital, was to meet or exceed the average 
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score for Magnet hospitals based on raw, unadjusted scores in the NRC Picker database.  The 
hospital had not met this target score in over 12 months, scoring at the 33rd percentile.  As of 
January 12, 2019, the community hospital FY 2019 performance to date improved to just below 
the 50th percentile as compared to all NRC database hospitals but remained at the 43rd percentile 
as compared to NRC database Magnet hospitals.  According to the NRC database analysis report, 
the community hospital’s pain management experience score was one of key drivers of patients’ 
overall rating of the community hospital, on a zero to 10 scale.  The surgical-orthopedic unit 
ranked third among its six community hospital units for pain management experience, scoring at 
the 30th percentile over the past 12 months.  
Since 2014, the community hospital had worked to implement the Assessment and 
Management of Acute Pain in the Hospitalized Adult CPG that recommended cognitive NPPMI.  
However, during annual surveys by the health system’s pain management APRN in 2016, 2017, 
and 2018, patients did not receive cognitive NPPMIs in the surgical-orthopedic unit or the other 
five inpatient units.  Similarly, other hospitals in the health system had low utilization of 
NPPMIs.  
Due to the lack of cognitive NPPMIs, lavender aromatherapy was recommended by the 
health system for nurses at each hospital to offer to patients.  This was particularly important for 
the community hospital and its surgical-orthopedic unit due to below-target patient pain 
management experience scores.  The selection of lavender aromatherapy was based on the 
literature review findings of the effectiveness of lavender aromatherapy for improved pain 
management in both acute and chronic pain, with a greater magnitude of benefit in acute pain 
(Lakhan, Sheafer, & Tepper, 2016).  In the placebo-control studies of lavender essential oil 
aromatherapy for acute pain, patients who received lavender aromatherapy demonstrated less 
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pain intensity than those who received placebo (Bagheri-Nesami, Espahbodi, Nikkhah, Shorofi, 
& Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 2015; Karaman et al., 2016; 
Kim et al., 2007).  The magnitude of effect of lavender aromatherapy, observed in a large 
observational trial in hospitalized patients, was a mean improvement in pain intensity score of 
three points on a 10-point scale (Johnson et al., 2016).  
Priorities.  
Since the community hospital resided in the state of Maryland, its patient experience 
scores determined 50% of the revenue from quality-based reimbursement (QBR) program 
(Health Services Cost Review Commission [HSCRC], 2017).  In other states, patient experience 
scores comprised only 25% of the value-based reimbursement program (HSCRC, 2017).  
Although the pain experience scores were removed from the FY 2019 QBR program, the overall 
rating of the hospital continued to be included and pain management experience was a key driver 
of the community’s hospitals overall rating.  Over a million dollars of the community hospital’s 
annual reimbursement was at risk under the QBR program (HSCRC, 2017). 
At the start of the project, the health system’s annual nursing goals included 
implementation of aromatherapy in all hospitals.  This logic model was developed to plan for the 
community hospital’s implementation of aromatherapy, fortify implementation with change 
agents, and focus on the surgical-orthopedic unit.  
Inputs. 
Lavender aromatherapy inhalers were placed in a dedicated bin in each nursing unit’s 
supply rooms by the supply chain team at the nurse managers’ direction.  The inhalers were 
financed through the unit nursing budget.  The inhalers used in the project had a three-month 
potency when opened, so only one inhaler was typically needed for each patient encounter.  
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Time and resources for training clinical staff on lavender aromatherapy inhalers included: 
• A 15-minute aromatherapy computer-based module for 25 clinical nurses on the 
surgical-orthopedic unit and four of the hospital’s nurse PCs.  
• Three 15-minute Lunch & Learn presentations with surgical-orthopedic unit 
nurses that occurred during a week-day day-shift, a week-day night-shift, and a 
week-end day shift.  
• Refreshments for the three surgical-orthopedic unit-based Lunch & Learn 
presentations and two nurse champion meetings, supplied by the DNP student. 
• Forty lavender aromatherapy inhalers were provided free of charge by the vendor 
through the hospital’s supply chain team and distributed to nurse PCs and clinical 
nurses on the surgical-orthopedic unit and other clinical staff during nurse PC 
meetings, Lunch & Learn presentations, and Rounding for Results sessions. 
Outcomes. 
Short-term outcomes. 
Surgical-orthopedic unit clinical nurses, nurse PCs, and other clinicians articulated: 
• Lavender aromatherapy benefits, patient assessment protocol and patient 
education key points.  
o The target for this outcome was all surgical-orthopedic unit clinical nurses 
and nurse PCs completed the computer module successfully with a score 
of 80% on the module evaluation. 
o The hospital nurse educator provided a de-identified health system 
learning management system report of lavender aromatherapy module 
completion. 
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• Intent to offer lavender inhalers to patients.  
o The target for this outcome was 100% of surgical-orthopedic unit nurses 
verbalize intent to offer lavender during DNP student weekly Rounding 
for Results sessions.  
o Evaluation was recorded on the DNP student surgical-orthopedic unit 
Rounding for Results form (Appendix K). 
• Skill to appropriately use and teach patients to use lavender inhalers. 
o The target for this outcome was 100% of surgical-orthopedic unit patients 
are observed to appropriately use lavender inhalers by the end of the 
fourth week of the DNP Rounding for Results sessions.  
o Evaluation was recorded on the DNP student surgical-orthopedic unit 
Rounding for Results form (Appendix K). 
• Nurse leaders established recommended par levels of lavender inhalers. 
o The target for this outcome was each week during DNP Rounding for 
Results sessions, the number of lavender inhalers was observed to be at 
par level for the day.  
o Evaluation was recorded on the DNP student surgical-orthopedic unit 
Rounding for Results form (Appendix K). 
• Nurse leaders mentioned lavender inhalers during nurse leader patient rounds. 
o The target for this outcome was each week during DNP student Rounding 
for Results sessions, a verbal check-in with the nurse manager or charge 
nurse validated that lavender aromatherapy was mentioned during their 
nurse leader rounds with patients.  
CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 28 
 
o Evaluation was recorded on the DNP student surgical-orthopedic unit 
Rounding for Results form (Appendix K). 
Medium-term outcomes. 
• Patients were screened for aromatherapy during the first four weeks of the project, 
during which the Rounding for Results sessions occurred. 
o The target for this outcome was 20% of adult surgical-orthopedic unit 
patients during week one of the project and increasing by 20% increments 
each week of the Rounding for Results sessions, to 80% on week four, 
measured by observations of documentation and electronic medical record 
reports. 
o Observations of documentation of screening of patients for lavender 
intolerance was recorded on the DNP student surgical-orthopedic unit 
Rounding for Results form (Appendix K). 
o Weekly EMR aromatherapy documentation reports were generated to 
provide percentage of patients with documentation of screening for 
contraindication or reaction to lavender essential oil (Appendix O).  These 
reports were run in one-week time-periods with only aggregate data 
reported.  
• Lavender inhalers were offered to appropriate patients in the surgical-orthopedic 
unit during the Rounding for Results sessions. 
o The target for aromatherapy offer was measured by documentation of 
patients’ verbal agreement decision in both the Rounding for Results 
observations and the weekly EMR aromatherapy documentation reports.  
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The target for aromatherapy offer to patients who did not have 
contraindication to lavender was 20% of adult surgical-orthopedic unit 
patients during week one of the project, increasing by 20% increments 
each week of the Rounding for Results sessions, to 80% of patients in 
week four.  To avoid placing undue pressure on nurses or patients no 
target was set for percent of patients without a contraindication who 
agreed to use the lavender inhaler. 
o Observations of documentation of patients’ verbal agreement decision to 
the offer of lavender inhaler were recorded on the DNP student surgical-
orthopedic unit Rounding for Results form (Appendix K). 
o Weekly EMR aromatherapy documentation reports provided percentage of 
patients without a contraindication to lavender aromatherapy who had 
documentation of the patient’s decision to the offer of lavender inhaler, 
including the percent of patients who verbally agreed to use it (Appendix 
O).  
• Patients self-administered the lavender inhalers as intended as measured by 
observations of patient use on weekly Rounding for Results sessions.  
o The target for this outcome was 100% of surgical-orthopedic unit patients 
were observed to self-administer lavender inhalers by the end of the fourth 
week of the DNP student Rounding for Results sessions.  
o Observations were recorded on the DNP student surgical-orthopedic unit 
Rounding for Results form (Appendix K). 
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Long-term outcomes. 
• Surgical-orthopedic unit patients’ pain was well managed as evidenced by pain 
experience scores.  
o The target for this outcome was surgical-orthopedic unit pain management 
experience scores at or above the NRC Picker database average score for 
Magnet hospitals by the end of the third quarter of FY 2019.  
o This outcome was measured by NRC Picker database reports that finalized 
eight weeks after the end of the project. 
• All appropriate patients were offered lavender inhalers to help manage pain in the 
two-week period after the Rounding for Results sessions ended.  
o The target for documentation of patients’ verbal agreement decision in 
period EMR report outcomes was 100% of adult surgical-orthopedic unit 
patients without a contraindication to lavender.  To avoid placing undue 
pressure on nurses or patients no target was set for percent of patients 
without a contraindication who agreed to use the lavender inhaler. 
o Weekly EMR aromatherapy documentation reports provided percentage of 
patients without a contraindication to lavender aromatherapy who had 
documentation of the patient’s decision to the offer of lavender inhaler, 
including the percent of patients who verbally agreed to use it (Appendix 
O).  
o Monthly supply chain reports evaluated if consumption matched the 
number of patients with documentation of agreement to use lavender 
CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 31 
 
aromatherapy noted in the EMR report for all three months of the project.  
There was no target for consumption as this was a validation measure.   
Assumptions. 
The following logic model pre-project assumptions were met and facilitated 
implementation success: 
• Lavender aromatherapy in the surgical-orthopedic unit was embraced by surgical-
orthopedic unit clinicians and patients as a valuable pain management 
intervention as assumed, but at a slower than anticipated rate. 
• Surgical-orthopedic unit patients agreed to use lavender aromatherapy. 
• Surgical-orthopedic unit clinical nurses implemented and completed the protocol 
but there were challenges such as uncertainty of inhaler location, 
misunderstanding of the eligible patient population, failure to screen all patients, 
nurse bias that patients receiving opioids would decline, and missing 
documentation of aromatherapy screening and offer. 
• The Iowa Model strategy of DNP student and nurse PC change agents was a valid 
approach for lavender aromatherapy implementation in the surgical-orthopedic 
unit population. 
• The community hospital CNO and the hospital Vice President for Medical Affairs 
supported nurse-directed lavender aromatherapy. 
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External Factors. 
The following external factors were evaluated to determine influence on the success of 
this logic model: 
• Lavender inhaler supply.  
o Supply remained available and there were no recalls or manufacturer 
interruptions.  The supply of lavender inhalers was sourced from one 
vendor in the Midwestern United States that supplied at least one other 
large health system. 
• Regulatory reviewers were an external factor that may have altered project 
implementation.  
o A Joint Commission presentation at the 2019 American Society of Pain 
Management Nursing conference noted that regulatory reviewers may 
have concerns because aromatherapy is not approved by the Food and 
Drug Administration (FDA) for the treatment of pain (Campbell, 2018). 
o The health system patient and family education material informed patients 
that aromatherapy could help patients manage pain, was not intended for 
treatment of disease, and was not regulated by the FDA.  
o The Joint Commission did not mention aromatherapy in its August 2018 
brief about NPPMIs (Joint Commission, 2018).  
o No regulatory reviews occurred at the community hospital during project 
implementation.  
• The Maryland hospital QBR program continued to include patient experience 
scores as 50% of the basis for QBR reimbursement (HSCRC, 2017). 
CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 33 
 
Setting 
The setting was an adult inpatient surgical-orthopedic unit at a community hospital in a 
10-hospital system.  
Study Population 
Inclusion criteria. 
• Community hospital clinical nurses and the nurse manager practicing on the adult 
inpatient surgical-orthopedic unit and nurse PCs were included in the project. 
• Adult inpatients or observation patients, ages 18 and older, experiencing acute or 
chronic pain or who have anticipated procedural pain, and who were cared for by 
clinical nurses and the nurse manager on the adult inpatient surgical-orthopedic 
unit were included in the project. 
• The community hospital’s lavender aromatherapy policy had the following 
exclusion criteria that aligned with those in the health system’s protocol: Adult 
inpatients or observation patients, ages 18 and older, experiencing acute or 
chronic pain or who were anticipated to have procedural pain.  
Exclusion criteria. 
• Nurses in the community hospital practicing in units other than the surgical-
orthopedic unit nurses or were not nurse PCs were excluded.  
• Pregnant women, prisoners, or non-English language speakers being cared for on 
the adult inpatient surgical-orthopedic unit were excluded.  Adults unable to 
verbally agree to receive lavender aromatherapy were excluded.  
• The community hospital’s lavender aromatherapy policy had the following 
exclusion criteria that aligned with those in the health system’s protocol:  
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o Any patient-reported intolerance or allergy to the lavender plant or 
essential oil including true allergy with anaphylaxis, rash, and/or 
intolerance such as headache, nausea, or dizziness induced by the odor. 
o Any cognitive or physical condition that rendered the patient unable to: (a) 
answer the aromatherapy assessment question regarding intolerance and 
allergy, (b) indicate verbal agreement to use the lavender inhaler, or (c) 
participate in education about lavender aromatherapy. 
Subject Recruitment 
This was an EBP project focused on the intervention of the Iowa model strategy of 
change agents in the practice environment to fortify the hospital’s lavender aromatherapy 
implementation, a hospital-approved NPPMI.  
Nurses from the community hospital’s surgical-orthopedic unit and the nurse PC program 
were recruited to participate in this project.  During the third quarter of FY 2019, the DNP 
student interacted with surgical-orthopedic unit clinical nurses, the surgical-orthopedic unit nurse 
manager, and community hospital nurse PCs.  The DNP student: (a) provided Lunch & Learn 
sessions; (b) encouraged clinical nurses and nurse PCs to complete the computer-based module 
training on aromatherapy; (c) conducted Rounding for Results sessions that included observation 
of  nursing documentation of aromatherapy in medical records, queries of nurses regarding their 
intent to offer aromatherapy, and observations of patients use of lavender aromatherapy inhalers; 
and (d) led discussions with nurse PCs about how to promote aromatherapy in the practice 
setting. The intent of the observations during the Rounding for Results sessions was to determine 
if the hospital’s policy and procedure for nurse-directed lavender aromatherapy was followed, to 
validate correct patient use of lavender aromatherapy inhalers, and provide re-education if 
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correct use was not observed.  No patient intervention other than nurse-directed lavender 
aromatherapy, a hospital-approved NPPMI, was provided.  No identifiable patient information 
was recorded.  The orthopedic-surgical unit Rounding for Results form did not include patient 
identifiers (Appendix K).   
Consent Procedure 
No consent process was performed because this was an EBP project to foster 
implementation of a hospital-approved nurse-directed NPPMI.  As per the community hospital’s 
aromatherapy policy, clinical nurses queried patients for self-reported contraindication or 
reaction to lavender essential oil, provided patient education regarding aromatherapy, and asked 
patients for verbal agreement to use aromatherapy before they provided lavender inhalers to 
patients.  The verbal agreement process was included in the health system protocol for lavender 
aromatherapy for pain management and community hospital’s nurse-directed aromatherapy 
policy and procedure based on the advice of the health system’s legal counsel, who also advised 
that written consent was not required.  Any patients who self-reported a contraindication or 
reaction to lavender essential oil were not offered the lavender inhaler.  No additional process to 
obtain consent occurred in this EBP project.  
Risks/Harms 
The potential risk to patients included harm due to allergic reaction or intolerance to 
lavender essential oil.  Patients who reported a history of allergy or sensitivity to lavender 
essential oil were not offered an inhaler.  A pulmonologist specializing in asthma management 
was consulted and after review of the evidence, recommended against including asthma on the 
list of contraindications (A. Shorr, personal communication, May 11, 2018).  Essential oils used 
in this project did not contain proteins and were highly unlikely to cause a Type I allergic 
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reaction (Buckle, 2015).  Allergy with IgG antibodies was a risk with exposure to essential oils, 
the same risk as any compound (J. Baraniuk, personal communication, May 23, 2018).  
However, this type of allergic reaction to essential oils has not been commonly reported (Buckle, 
2015).  Use of lavender essential oil has not been associated with clinical worsening of asthma 
(Buckle, 2015).  Seven clinical trials reported no serious patient events (Bagheri-Nesami, 
Espahbodi, Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 
2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2006; Kim et al., 2007).  Two health 
systems, Allina Health and New York Presbyterian, reported no serious patient or associate 
safety events with use in multiple hospitals over multiple years (Joswiak et al., 2016; J. Seley, 
personal communication, May 30, 2018).  No patient, visitor, nurse, physician, or other associate 
safety events were reported in the product trial at two of the community hospitals’ sister health 
system hospitals in August 2018.  No patient, visitor, nurse, physician, or other associate safety 
events were reported during this project. 
No demographic or other identifying data was captured for this project and only 
aggregate data were reported.  There was no risk of patient identification in the collected or 
reported data. 
Potential benefits included: 
• Nurses may have experienced increased role satisfaction through the opportunity 
to impact patients’ pain experience and personal wellness using the lavender 
inhalers for personal use. 
• Patients may have experienced improved pain management through use of 
lavender aromatherapy including decreased need for analgesic medications, 
including opioids.  Patients who were observed to be using the inhaler incorrectly 
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experienced enhanced safety and effectiveness of aromatherapy through re-
education that was provided by the DNP student. 
Subject Costs and Compensation 
There were no costs to subjects for the aromatherapy inhalers.  The aromatherapy 
inhalers were non-chargeable items provided through the unit cost centers.  Clinical nurses were 
provided lavender inhalers for personal use as part of the educational sessions and these were 
supplied free of charge from the lavender inhaler vendor.  Clinical nurses on the surgical-
orthopedic unit and nurse PCs participated in training and meetings during worked hours.  
Refreshments for the PC meetings and Lunch & Learn sessions were provided by the DNP 
student. 
Study Interventions 
The study interventions employed the strategy of a DNP student and nurse PC change 
agents through the following activities: 
• Encouragement of nurses to complete an aromatherapy computer-based training module 
during the following interactions: nurse PC meetings, Lunch & Learn presentations, and 
Rounding for Results sessions. 
• Two DNP student-facilitated nurse PC meeting discussions regarding how to promote 
aromatherapy use (Appendix J).  
• Three Lunch & Learn aromatherapy presentations for surgical-orthopedic unit clinical 
nurses (Appendix H). 
• Four DNP student-led Rounding for Results sessions with clinical nurses on the surgical-
orthopedic unit (Appendix K). 
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• Development of reports including supply chain monthly lavender inhaler usage and EMR 
aromatherapy documentation reports that nurse PCs reviewed at their meetings and 
planned to review on an ongoing basis. 
Outcomes Measured 
Short-term, medium-term, and long-term outcomes were measured as noted in the Logic 
Model (Appendix N). 
Project Timeline 
Congruent with the community hospital aromatherapy implementation action plan in 
Appendix P, the project began on February 14, 2019 and was completed on March 30, 2019.  
Lunch & Learn presentations occurred on February 14, 2019 and February 16, 2019.  Rounding 
for Results sessions occurred on February 19, 2019; February 26, 2019; March 5, 2019; and 
March 12, 2019.  Nurse PC discussions occurred on February 28, 2019 and March 27, 2019.  
Weekly aromatherapy reports contained data from February 17, 2019 through March 30, 2019.  
The action plan incorporated the Iowa model recommendation to include strategies for all four 
phases of practice change (Cullen et al., 2018).  
Resources Utilized 
Lavender aromatherapy inhalers for patients were financed by the budgets of all inpatient 
nursing units, including the surgical-orthopedic unit, and located in a dedicated space on the 
units’ supply rooms.  
Forty lavender aromatherapy inhalers were provided to clinical staff, including four nurse 
PCs, to try personally and were secured free of charge by the vendor through the hospital’s 
supply chain team. 
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Time and resources for training clinical staff on lavender aromatherapy inhalers was 
provided.  This included: 
• A 15-minute aromatherapy computer-based module for 24 clinical nurses on the 
surgical-orthopedic unit and four hospital nurse PCs.  
• Three 15-minute Lunch & Learn sessions for nurses at three sessions. 
• Two aromatherapy discussions at the regular monthly nurse PC meetings that 
were approximately 30 minutes in length. 
• Refreshments for three nurse PC meetings and three surgical-orthopedic unit-
based Lunch & Learn sessions for clinical nurses on the surgical-orthopedic unit 
were supplied by the DNP student. 
Evaluation Plan 
Observational data was captured on the DNP student Rounding for Results form with no 
patient identifiable data (Appendix K).  EMR reports of aggregate data derived from 
aromatherapy documentation fields on the surgical-orthopedic unit were generated weekly by the 
health system informatics team and supplied to the DNP student as de-identified cases 
(Appendix O).  Inhaler consumption reports were supplied by the hospital supply chain team via 
email to the DNP student.  A password-protected Excel workbook was used for data capture and 
analysis (Appendix Q). 
Data Analysis, Maintenance & Security  
The data analysis plan was comprised by three appendices: (a) plan for project primary 
clinical question data analysis (Appendix R), (b) plan for project aims data analysis (Appendix 
S), and (c) plan for project logic model outcomes data analysis (Appendix T).  No tests of 
statistical significance were performed.  Descriptive statistics are provided for categorical and 
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numerical data compiled from the DNP student Rounding for Results form, the weekly de-
identified EMR aromatherapy documentation reports, and the hospital supply chain team inhaler 
consumption reports.  Qualitative data including barriers, facilitators and comments compiled on 
the DNP student Rounding for Results form were categorized and summarized in the Excel 
workbook and noted in the reporting of results.  Weekly EMR aromatherapy documentation 
report data were transcribed into the same Excel workbook as the Rounding for Results forms.  
The Excel worksheets were queried for empty cells.  No identified data were stored.  The Excel 
workbook was a password-protected file stored on a password-protected health system-owned 
laptop with the organizational antivirus and threat protection software.  Backup files were 
password protected and stored on a password-protected and encrypted USB drive compliant with 
the health system standards.  No paper copies of Rounding for Results forms were stored.  No 
paper copies or electronic files of the EMR aromatherapy documentation reports were stored.  
Anticipated Findings 
Rates of clinical nurse and patient participation were anticipated to be low initially and to 
increase over the course of the project.  This pattern was anecdotally observed in the pilot at 
another hospital in the health system where it was noted that nurse interest increased when 
patients described the effectiveness to their nurses and when nurses observed a lessening of pain 
because of the use of the lavender inhaler.  
Anticipated barriers were: (a) nurses’ hesitancy to add another task to their already busy 
clinical day and (b) patient disinterest in aromatherapy, although this was not observed in the 
pilot.  
It was anticipated that the addition of nurse PC support and DNP student Rounding for 
Results sessions would promote lavender aromatherapy utilization.  Sustainment and integration 
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of aromatherapy use through the nurse PC program’s ongoing aromatherapy promotion and data 
review was anticipated.  Improvement of HCAHPS pain management experience scores was 
expected.  Decreases in pain intensity and opioid medication use in patients who receive 
aromatherapy reported in the literature were possible outcomes.  
Results 
Primary Clinical Question Results  
The results for the primary clinical question “Was the strategy of change agents effective 
in achieving implementation of nurse-directed lavender aromatherapy to improve pain 
management experience in adult patients on a surgical-orthopedic unit of a community hospital?” 
included measures of intervention feasibility and the clinical outcome of improved patient pain 
experience (Appendix U).  
Interventions Results 
The logic model output activities, which engaged change agents, included: three DNP 
Student-led Lunch & Learn presentations, four DNP student-led weekly Rounding for Results 
sessions and two DNP-facilitated nurse PC discussions.  All three interventions were feasible and 
the project outcome of implementation of the bundle of all three interventions was met.  
Three Lunch & Learn presentations were attended by a total of 21 surgical-orthopedic 
unit associates.  The range among roles of attendees was: 14 Registered Nurses, six Certified 
Nursing Assistants, and one Unit Secretary.  The number of attendees per presentations ranged 
from five to nine.  The mean number of attendees per presentation was seven.  
Four DNP student-led weekly Rounding for Results sessions were completed with a total 
of 78 patients, a mean of 20 patients evaluated per session, and a range of 18-21 patients per 
session.  
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Two DNP-facilitated nurse PC discussions were attended by four nurse PCs and three to 
four PC program leaders at each session, including the DNP student, with a mean attendance of 
7.5 and a range of seven to eight attendees.  Although 14 nurse PCs were anticipated to 
participate in the program, only four attended either meeting and three attended both meetings.  
The nurse PCs represented four of seven inpatient medical-surgical units, including the surgical-
orthopedic unit.   
Clinical Outcome Results 
The intervention of engaging change agents was effective in achieving implementation of 
nurse-directed lavender aromatherapy to improve pain management experience in adult patients 
on a surgical-orthopedic unit of a community hospital.  The surgical-orthopedic unit patient pain 
management experience percentile rankings increased during the implementation period.  Before 
implementation the surgical-orthopedic unit scores were below target.  In the first quarter, the 
scores were 52.2% positive, ranking in the 12th percentile as compared to Magnet hospitals in the 
NRC Picker data base.  In the second quarter, the scores were 63.0 % positive, ranking in the 43rd 
percentile, but the reliability of the second quarter scores was limited by a small sample size.  
After implementation in the third quarter, the surgical-orthopedic unit score increased to 72.2% 
positive, ranking at the 78th percentile and exceeding the target.  Before implementation the 
community hospital score was: (a) below target in the first quarter at 59.3% positive, ranking in 
the 31st percentile; and (b) above target in the second quarter at 63.3 % positive, ranking in the 
56th percentile.  After implementation in the third quarter, the community hospital score 
decreased below target at 64.1% positive, ranking at the 46th percentile.  Although the surgical-
orthopedic unit scores and ranking increased markedly during implementation, the community 
hospital ranking decreased slightly, although the score itself increased. 
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Project Aims Results 
Project aims data are reported in Appendix V. 
The first project aim was to increase the surgical-orthopedic unit patient HCAHPS pain 
management experience score to equal or above the Magnet average of hospitals in the NRC 
Picker database by the end of the third quarter of FY 2019.  This aim was met with a score of 
72.2% positive that ranked at the 78th percentile.   
The second aim was 100% of surgical-orthopedic unit patients who were documented to 
have no contraindication to lavender aromatherapy receive an offer of lavender aromatherapy 
each of the six weeks of the project.  This aim was not met but was nearly achieved.   
Based on surgical orthopedic unit EMR data, 33 of 34 eligible patients received the offer, 
missing the aim by one patient on week three.  The range of weekly percentages was 91.7% on 
the third week to 100% on the other five weeks.  The mean weekly percentage was 97.1%.  
Based on the total of the four weekly Rounding for Results session observations of medical 
records, eight of nine patients, 88.89%, who had documentation of no contraindication to 
lavender aromatherapy received an offer of lavender aromatherapy.  Of the nine patients who 
were screened, one declined the offer, so the nurse did not chart the education or response to the 
offer.  The DNP student re-educated the nurse on the protocol and she verbally indicated she 
would correct the documentation when she next charted. 
The frequency that patients were screened impacted the reliability of the measure.  The 
rates of documentation of screening for lavender contraindication in the EMR aromatherapy 
documentation reports ranged from 16.7% to 50.0% of surgical-orthopedic unit patients weekly.  
During the four Rounding for Results sessions, 38 of 78 patients, 49%, were potential users of 
aromatherapy, because they were not cognitively impaired and could verbalize agreement to use 
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the aromatherapy, which was a required element in the hospital policy.  Only nine of these 38 
patients, 23.7%, were observed to have screening for contraindication documented.  One patient 
was screened but did not receive education.  Eight patients had documentation of an offer for 
aromatherapy and the other patient who was offered but declined did not have this documented. 
Nurses were often engaged in other patient care activities during the Rounding for 
Results sessions, which did not allow time for them to be directly mentored by the DNP student.  
Nurses were willing to offer aromatherapy and indicated they would assess the patients later in 
the shift.  Based on the EMR data during that same four-week period, 24 of 25 patients with no 
documentation of contraindication received aromatherapy as compared to eight patients during 
the Rounding for Results sessions.  These data confirm that nurses screened and offered patients 
aromatherapy outside of the Rounding for Results sessions. 
Logic Model Outcomes 
Logic model outcomes data are reported in Appendix W. 
Short-term outcome results. 
The first short-term outcome was that surgical-orthopedic unit clinical nurses, nurse PCs, 
and other clinicians would articulate lavender aromatherapy benefits, the patient assessment 
protocol, and key points for patient education demonstrated by a score of at least 80% on the 15-
minute computer-based aromatherapy learning module post-test.  This outcome was met for all 
surgical-orthopedic unit clinical nurses because all 24 successfully completed the post-test.  The 
outcome was met for all four nurse PCs who verbally indicated they completed the module.  
However, the verbal reports could not be validated with queries by name, since the learning 
management system report was de-identified.  It was not possible to determine the percentage of 
all clinicians who completed the module.  In addition to the surgical-orthopedic clinical nurses, 
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an additional 305 community hospital associates successfully completed the module for a total of 
329 associates: 225 clinical nurses practicing in direct care, 32 certified nursing assistants, 18 
nurse leaders, 12 technicians, 11 non-direct care nurses, 10 unit-secretaries, eight physicians’ 
assistants/surgical assistants five transporters, three advanced practice registered nurses, two 
nurse educators, two licensed practical nurses and one physician.  
The second short-term outcome measured the intent of surgical-orthopedic unit clinical 
nurses to offer lavender inhalers to patients.  The target for this outcome was 100% of surgical-
orthopedic unit nurses would verbalize intent to offer lavender during DNP student weekly 
Rounding for Results.  This outcome was not met but was nearly achieved.  During the first three 
of four weekly Rounding for Results sessions, all nurses on duty articulated to the DNP student 
their intent to offer lavender aromatherapy inhalers to patients.  On the final week, five of the six 
nurses on duty also indicated intent to offer lavender aromatherapy inhalers to patients.  The 
remaining nurse was very busy caring for several complex patients.  The nurse understandably 
commented that providing aromatherapy was not a priority and she did not have time to discuss 
aromatherapy at all.  In summary, in 22 of 23 encounters, 96% of the time, nurses indicated 
intent to offer lavender aromatherapy inhalers.  
The third short-term outcome was surgical-orthopedic unit clinical nurses would 
demonstrate the skill to appropriately use and teach patients to use lavender inhalers measured by 
observation of surgical-orthopedic patient use of the inhalers.  The target for this outcome was 
100% of surgical-orthopedic unit patients who received inhalers would demonstrate correct use 
by the end of the fourth week of the DNP Rounding for Results sessions.  This outcome was not 
met.  Only three of eight patients, 37.5%, demonstrated and verbalized correct use.  On weeks 
one, two, and three, 50% of patients, one per week, correctly verbalized and demonstrated use, 
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and on week four neither patient of the two patients verbalized and demonstrated correct use.  
All patients were given written instructions that the nurses verbally reviewed with them.  The 
written instructions were at a fifth-grade reading level and were vetted by a health literacy 
expert.  Of the five patients who required re-education on lavender aromatherapy inhaler use, all 
misunderstood the frequency of use.  The inhaler can be used up to four times per hours.  Four 
patients stated it could be used only every four hours and one stated every six hours.  No patients 
were observed to use the device in an unsafe manner; one patient was unsure how near to the 
nose to hold the inhaler.  Several of these patients had recently been admitted to the unit and 
some were in the immediate post-operative period, which may have limited understanding of the 
instructions. 
The fourth short-term outcome was surgical-orthopedic unit nurse leaders would establish 
recommended par levels of lavender inhaler.  The target for this outcome was each week during 
DNP Rounding for Results sessions, the number of lavender inhalers would be observed to be at 
par level for the day in the unit’s supply rooms.  This outcome was met.  On all four weeks the 
DNP student observed inhalers were available in both supply rooms of the unit.  Nurse leaders 
established recommended par levels of lavender inhalers initially at five inhalers per supply 
room and on the second week increased the number to 10 inhalers per supply room.  At the time 
of the Rounding for Results sessions, which occurred in the afternoon hours each week, the 
number of inhalers in the supply room bins ranged from three to 10.  Accounting for inhalers 
placed in use earlier in the day, the par levels were adequate. 
The fifth short-term outcome was that the surgical-orthopedic unit nurse leaders would 
verbally report to the DNP student that they mentioned lavender aromatherapy inhalers to the 
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patients during nurse leader patient rounds on all four weeks of the Rounding for Results 
sessions.  This outcome was met.  
Medium-term outcome results. 
The first medium-term outcome was surgical-orthopedic patients would be screened for 
aromatherapy during the first four weeks of the project.  The target for this outcome was 20% of 
adult surgical-orthopedic unit patients during week one of the project, increasing by 20% 
increments each week of the Rounding for Results sessions, to 80% on week four.  This outcome 
was measured by observations of documentation during the Rounding for Results sessions and 
the EMR aromatherapy documentation reports.  
In the Rounding for Results sessions, the target was not met on any of the four weeks.  In 
all four weeks combined only nine of 38 patients, 23.7%, who could have potentially benefited 
from lavender aromatherapy were screened at the time of the Rounding for Results sessions.  
Screening ranged from 16.7% of patients on the first and second weeks to 50% of patients on 
third week to 25% of patients on fourth week.  Patients were excluded if they did not report pain 
or if their cognitive status prevented education about aromatherapy or the ability to verbally 
agree to use aromatherapy.  Barriers observed during Rounding for Results sessions included: (a) 
a patient having nausea at the time of rounds; (b) lack of documented pain assessment; (c) 
nurses’ decisions not to document the aromatherapy assessment when patients declined to use it; 
(d) one nurse’s misperception that lavender aromatherapy was limited to only post-operative 
orthopedic procedure patients, despite the policy to offer to all patients having pain; (e) travel 
nurses’ lack of awareness of lavender aromatherapy because they were not provided the lavender 
aromatherapy computer-based training and did not attend the Lunch & Learn presentations; (f) 
nurses’ difficulty finding the lavender aromatherapy inhalers in the supply room until shown the 
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location by the DNP student; and (g) nurses stated-bias that patients receiving opioids would 
decline the lavender aromatherapy, so they did not ask these patients. The nurse who thought 
lavender aromatherapy was limited to only post-operative orthopedic procedure patients 
misunderstood a nurse leader who asked that nurses focus on this group of patients.  The nurse 
leader had not intended her comment to exclude other patients having pain.  Eight patients 
reported pain on previous days when lavender aromatherapy should have been considered but 
their pain resolved at the time of the Rounding for Results session; these patients were included 
in the denominator.    
In the weekly EMR aromatherapy documentation reports, the target was only met on the 
first week when 25% of patients had documentation of screening and the target was 20%, the 
lowest of the four weekly targets.  In all four weeks combined only 25 of 149 patients, 16.7%, 
who were admitted to the unit had documentation of screening.  Screening ranged from 3.1% of 
surgical-orthopedic unit patients on the fourth week to 26.7% patients on the third week.  
However, the surgical-orthopedic unit screened more patients that the other six inpatient 
units combined.  Over this same four-week period, only 34 of 4,112 patients on all seven 
inpatient units, including the surgical-orthopedic unit patients, had documentation of screening 
for aromatherapy.  This was less than one percent of patients compared with 16.7% of patients 
admitted to the surgical-orthopedic unit.  These 34 surgical-orthopedic unit patients constituted 
61% of all community hospital patients screened for aromatherapy.  The comparison of weekly 
percentages of patients screened for lavender aromatherapy on the surgical-orthopedic unit to all 
inpatient units is provided in a run chart (Appendix X).  
The second medium-term outcome was appropriate surgical-orthopedic patients would be 
offered lavender aromatherapy during the first four weeks of the project.  The target for this 
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outcome was 20% of adult surgical-orthopedic unit patients during week one of the project, 
increasing by 20% increments each week of the Rounding for Results sessions, to 80% on week 
four.  This outcome was measured by observations of documentation during the Rounding for 
Results sessions and the weekly EMR aromatherapy documentation reports.  To avoid placing 
undue pressure on nurses or patients no target was set for percent of patients without a 
contraindication who agreed to use the lavender inhaler. 
In the Rounding for Results sessions, the target was met all four weeks.  Documentation 
of aromatherapy offer was observed in eight of the nine patients, 88.89%, who were screened 
over the four-week period.  
In the weekly lavender aromatherapy EMR reports, the target was met three of four 
weeks: Documentation of aromatherapy offer was observed in 100% of patients who were 
screened in the first, second, and fourth weeks and 92% of patients in the third week.  In all four 
weeks combined 24 of 25 patients, 96%, who were screened for aromatherapy were offered 
aromatherapy.  As previously discussed, there were likely more patients who were appropriate 
for aromatherapy who were not screened.  The frequency that patients were screened impacted 
the reliability of the measure both in the Rounding for Results data and the electronic medical 
reports data.   
 There was no target for percent of patients without a contraindication to agree to use the 
lavender inhaler to avoid placing undue pressure on nurses or patients.  The documentation data 
in the weekly EMR aromatherapy documentation report indicated all 24 patients who were 
screened and offered aromatherapy agreed to use it.  This may be an overestimation of patient 
agreement to use lavender aromatherapy because the DNP student observed during the Rounding 
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for Results sessions that nurses did not consistently document the aromatherapy assessment 
when patients declined.  
The third medium-term outcome was self-administration of the lavender inhalers as 
intended, measured by observations of patient use during each weekly Rounding for Results 
session.  The target that all surgical-orthopedic unit patients who received inhalers would 
demonstrate correct use was not met on any of the four weeks.  Only three of eight patients, 
37.5%, demonstrated and verbalized correct use.  Additional discussion of this outcome is 
located on pages 45-46.   
Long-term outcome results. 
The long-term outcome of well-managed patient pain experience was met, evidenced by 
surgical-orthopedic unit pain management experience scores at or above the NRC Picker 
database average score for Magnet hospitals by the end of the third quarter of FY 2019.  As 
noted on in the evaluation of the primary clinical question on page 42, the surgical-orthopedic 
unit patient pain management experience improved by 35 percentile ranks during the 
implementation period.  Before implementation, the surgical-orthopedic unit scores were below 
target.  In the first quarter, the scores were 52.2% positive, ranking in the 12th percentile as 
compared to Magnet hospitals in the NRC Picker data base.  In the second quarter, the scores 
were 63.0 % positive, ranking in the 43rd percentile, but the second quarter scores reliability was 
limited by a small sample size.  In the third quarter, during implementation of lavender 
aromatherapy, the surgical-orthopedic unit score increased to 72.2 percent positive ranking at the 
78th percentile.  
Before implementation, the community hospital scores were below target in the first 
quarter at 59.3% positive, ranking in the 31st percentile, and above target in the second quarter at 
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63.3 % positive, ranking in the 56th percentile.  After implementation in the third quarter, the 
community hospital score decreased below target at 64.1% positive, ranking at the 46th 
percentile, although the score itself increased.  While the surgical-orthopedic unit scores 
increased 35 percentile ranks during implementation, the community hospital scores decreased 
10 percentile ranks. 
The second long-term outcome that all appropriate surgical-orthopedic unit patients were 
offered lavender inhalers during weeks five and six of the project was met.  This outcome was 
measured by the weekly EMR aromatherapy report.  Weeks five and six occurred after the 
Rounding for Results Sessions were finished.  Appropriate patients were defined as those with 
documentation of screening and no contraindication to lavender aromatherapy.  The outcome 
denominator included only the nine patients with documentation of screening as compared to the 
71 patients admitted to the unit during those two weeks including: seven of 41 patients, 17.5%, 
admitted the fifth week and two of 31 patients, 6.5%, admitted the sixth week.  All nine of the 
patients had documentation that they verbally agreed to use lavender aromatherapy.  In the six 
weeks of the project combined, only 34 of 220 surgical-orthopedic unit patients, 16%, had 
documented screening.  The effectiveness of this measure relied on patients being screened and 
this screening documented.  As discussed previously, the frequency that patients were screened 
impacted the reliability of the measure.   
Use of lavender aromatherapy was also measured indirectly through monthly supply 
chain consumption reports of lavender inhalers.  Consumption was compared to the number of 
patients with documented agreement to use an inhaler.  In February and March on the surgical-
orthopedic unit, 144 inhalers were consumed as compared with only 33 patients who were 
documented as agreeing to use an inhaler.  During this same time on all inpatient units, including 
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the surgical orthopedic unit, 419 inhalers were consumed as compared with 55 patients who were 
documented as agreeing to use the inhalers.  
Possible reasons for the discrepancy between inhaler consumption and the number of 
patients documented as agreeing to use an inhaler were: (a) patients used more than one inhaler, 
which was noted on more than one occasion when a nurse did not realize the patient already had 
one; (b) inhaler use was not documented because some nurses indicated they were not sure 
where to document but provided the inhaler; and (c) inhalers were removed by clinicians but not 
given to the patients. The inhalers were a non-charge item and could be removed by anyone with 
access to the supply room.   
In the month following the project, inhaler consumption increased in both the surgical-
orthopedic unit and all inpatient units combined.  The surgical-orthopedic unit monthly inhaler 
consumption was 69 the first month, 75 the second month, and 79 the month after the project.  
The combined inpatient inhaler consumption was 207 the first month, 212 the second month, and 
250 the month after the project.  Over the three-month period, the surgical-orthopedic unit 
consumed 33% of the inhalers purchased by the community hospital inhalers, while the unit’s 
patient volume was only 3.5% of hospital inpatient admissions.   
Discussion 
Implications for Practice 
The change agent strategy of Rounding for Results and Lunch & Learn sessions on the 
surgical-orthopedic unit was feasible and effective.  The surgical-orthopedic unit implemented a 
disproportionate majority, 61%, of the community hospital’s documented screenings for 
aromatherapy and was responsible for 33% of the hospital’s consumption of lavender inhalers, 
despite only admitting 3.5% percent of all inpatients.  Surgical-orthopedic unit pain experience 
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scores increased by 35 percentile ranks and met the Magnet hospital average target during 
implementation, while the community hospital overall decreased by 10 percentile ranks and did 
not meet the Magnet hospital average target.  
The DNP student change agent had the opportunity to identify and mitigate point of care 
barriers that are often unforeseen in the project planning stage.  In this project, the DNP student 
mitigated the barriers observed in the Rounding for Results sessions as follows: (a) assisted 
nurses with locating the inhalers; (b) communicated the difficulty locating inhalers to the nurse 
leaders, who then assisted nurses on all shifts to find them; (c) identified travel nurses had not 
completed the computer-based module and communicated this to the nurse educator, who then 
corrected the learning plan for travel nurses; and (d) observed nurses’ bias that patients who were 
receiving opioids would not want to try the lavender aromatherapy and addressed it by role 
modeling the discussion with these patients at the bedside and communicating aromatherapy 
patient success stories to the nurses.  
In addition to the computer-based learning module that was completed by nurses in all 
health system hospitals, the surgical-orthopedic unit nurses received: (a) Lunch & Learn sessions 
attended by 14 of the 24 nurses; (b) real-time coaching by the DNP student during four Rounding 
for Results sessions; and (c) aromatherapy huddles provided by the unit nurse PC in provided to 
multiple shifts during the project.  Despite the enhanced education and coaching, the adoption of 
the practice change of lavender aromatherapy was slower than anticipated.  Computer-based 
modules provided basic knowledge for the practice change, while point-of-care rounding 
provided reminders, role modeling, and information clarification.  Point-of-care rounding 
facilitated commitment, action and adoption of the change, but not as rapidly as expected.  
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The impact of the change agent strategy of unit-based pain champions was limited in this 
project for several reasons: (a) only four of the seven units were represented at the nurse PC 
program meetings when aromatherapy was discussed; (b) the nurse PC program was new and the 
aromatherapy discussions occurred just after inception, in the programs’ second and third 
meetings; and (c) aromatherapy was the first project implemented by the nurse PCs. Transition to 
new nursing roles often take at least one year (Gunnarsdottir et al., 2017).  Several nurse PCs 
indicated initial hesitancy to discuss practice change with peers and uncertainty as to how to 
conduct unit-based huddles to promote aromatherapy.  The four nurse PCs overcame these 
challenges and reported promoting aromatherapy on their units through huddles and/or peer 
coaching.  
Implications for Healthcare Policy 
DNPs possess the knowledge, skills and attitudes required to act as change agents to 
foster action and adoption and sustainment and integration of EBP (Kleinpell, 2014).  This 
project required DNP competencies for: (a) location, appraisal and synthesis of evidence; (b) 
project development and execution through a logic model; (c) incorporation of the Iowa model 
dissemination strategy of change agents; (d) utilization of EMR documentation data; (e) patient 
advocacy; and (e) advanced practice mentorship of clinical nurses (American Association of 
Colleges of Nursing [AACN], 2006; Taylor-Powell et al., 2003). Funding is needed to develop 
high-quality research to measure the impact of the DNP role on EBP implementation (Kleinpell, 
2014).  For example, the review of the literature, spanning over 25 years, regarding the nurse PC 
role revealed: (a) only one randomized controlled trial that was conducted in Iceland, and (b) 15 
observational and qualitative studies from Australia, Canada, China, and the United States (Allen 
et al., 2018; Eaton et al., 2013; Ferrell et al., 1993; Grant et al., 2011; Greenway & Corston, 
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2016; Gunnarsdottir et al., 2017; Holley et al., 2005; Kaasalainen et al., 2015; Ladak et al., 2013; 
McCleary et al., 2004; McMillan, Tittle, Hagan, & Small, 2005; Overstreet, 2012; Paice et al., 
2006; Telford, Nichols, & Watson, 2019; Tong et al., 2019). Additional high-quality nurse PC 
research studies are needed to identify key interventions for nurse PCs and DNP/APRN mentors 
and demonstrate clinical outcomes. 
The challenge of funding nurse PC programs was described across geographic locations, 
settings of community hospitals and academic medical center, and throughout the 25-year 
timespan of the literature (Allen et al., 2018; Grant et al., 2011; Gunnarsdottir et al., 2017; Ladak 
et al., 2013; McCleary et al., 2004; McMillan, Tittle, Hagan, & Small, 2005; Tong et al., 2019).  
Nurse PCs require funding to advance their subject matter expertise through educational 
conference attendance, meet as a community of practice, and do the work of improving practice 
by conducting unit-based education, rounds, and quality improvement projects.  Policy is needed 
to promote, fund, and recognize the resources required to implement and sustain this role.  
Implications for Executive Leadership 
The role of executive leadership in change initiatives includes: (a) evaluating if the 
proposed initiative is likely to create excellence; (b) identifying and securing the resources 
required for the initiative to achieve excellence; (c) communicating the requirements to key 
stakeholders from other disciplines and within nursing, including clinical nurses, unit nursing 
leaders, nursing informatics specialists, nursing practice specialists, nursing quality specialists, 
and nursing professional development specialists; and (d) setting a cadence for data-driven 
reporting of initiative milestones and impact to key stakeholders (McBride, 2011) . The 
community hospital CNO evaluated the potential of the project to improve patient pain 
experience that was an organizational priority with both reputational and financial impact for the 
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hospital.  The CNO communicated her support to: (a) the hospital President and the Vice 
President for Medical Affairs; (b) the senior director for nursing who engaged unit managers, 
nurse educators, and the supply chain leader to support the initiative; and (c) all associates, by 
authoring a hospital newsletter article in collaboration with the DNP student.  The CNO also 
invited the DNP student to present the project overview including information about lavender 
aromatherapy and the role of the DNP student and nurse PC change agents to the hospital Patient 
and Family Quality and Safety Council.  The surgical-orthopedic unit nurse manager supported 
the initiative by: (a) attending one of the Lunch & Learn sessions to show support; (b) ensuring 
that lavender aromatherapy was included in nurse leader rounds with patients, which was 
verbally validated each week at the Rounding for Results sessions; and (c) reinforcing the 
importance of lavender aromatherapy as part of her role as the hospital leader of the nurse PC 
program.  
Despite these key tactics, the adoption of the practice change was slower than anticipated, 
even on the surgical-orthopedic unit.  The project was structured with a six-week timetable, a 
logic model, and more educational and coaching interventions than typical for the community 
hospital to include in a practice change project.  The logic model addressed anticipated 
challenges but did not identify all challenges encountered, including the slower than expected 
adoption of the practice change.  The experience of slow and complex practice change was 
consistent with the findings of a survey of CNOs: 44% did not feel EBP could be implemented in 
timely manner and half were unsure of the steps required for a successful practice change 
(Melnyk et al., 2016).  Based on Rounding for Results sessions observations by the DNP student, 
the community hospital CNO requested additional rounds by the hospital’s CNS and nurse 
educators to assist clinical nurses on all units in locating the lavender inhalers and documenting 
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aromatherapy.  Like the community hospital CNO, executive leaders may need to fortify practice 
change with additional resources.   
Implications for Quality/Safety 
Most patients who agreed to use it lavender aromatherapy did not understand the 
frequency correctly, despite receiving education.  These patients thought aromatherapy could 
only be used hours apart instead of four times an hour, which could have limited the impact for 
pain management.  The patient education material had been vetted with a health literacy expert 
for readability, was fifth grade level, and was only one page in length.  However, patient 
readiness to learn was limited because patients often had undergone a surgical procedure or had 
just arrived on the surgical-orthopedic unit.  Use of the teach-back technique, for bi-directional 
communication between patient and nurse, had been promoted by the community hospital’s 
health system (Brown, Mack, Guzetta, & Tefera, 2014).  However, based on the observations of 
these patients, clinical nurses may not have been comfortable or felt they had time to use teach-
back as part of the patient education process.  Evaluation of the effectiveness of lavender 
aromatherapy education effectiveness was required to achieve quality and safety.   
Development and utilization of EMR reports was another feature of this project.  The 
EMR aromatherapy documentation report was designed to measure the frequency of patient 
screening and offers of aromatherapy.  However, without establishment of benchmarks for the 
percentage of patients who were candidates for aromatherapy, the report’s meaning to nurse 
leaders was limited.  Based on the Rounding for Results observations, a recommendation was 
made to limit the patient denominator to only those with pain to improve its usefulness.  The 
comparison of the supply chain data to the EMR reports revealed lavender aromatherapy 
documentation did not match actual patient use.  This was shared with nurse PCs who worked to 
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foster accurate documentation on their units.  EMR reports were a useful tool to evaluate the 
practice change but required point-of-care validation to ensure quality. 
Although patient allergic reaction to lavender aromatherapy is rare, one patient observed 
in the Rounding for Results session verbalized a pre-existing intolerance, so no lavender 
aromatherapy inhaler was provided (Buckle, 2015).  Intolerance screening as a component of 
nurse-directed lavender aromatherapy was an important safety process.    
Plans for Sustainability and Future Scholarship 
The integration and sustainment strategy for lavender aromatherapy included a plan for 
ongoing nurse PC unit activities: review of EMR aromatherapy documentation reports, review of 
patient pain management experience scores, observation of patient aromatherapy use, audits of 
EMR documentation, and educational huddles for peers.  The hospital’s CNS planned to 
continue to mentor the nurse PCs, monitor lavender aromatherapy documentation and patient 
experience scores, and provide unit-based pain rounds that included promoting the use of 
lavender aromatherapy.  The community hospital’s nurse PC program was part of the health 
system’s nurse PC program that included ongoing review of system-wide EMR aromatherapy 
documentation reports and patient experience data, promotion of best practices for pain 
management through nurse PC system meetings, and facilitation of monthly PC program leader 
meetings.  The hospital’s CNS was also a member of a system-wide committee of nursing 
practice leaders that conducted ongoing review of system-wide EMR aromatherapy 
documentation reports and patient experience data.  
The Rounding for Results observations provided observations to improve the utility of 
the EMR aromatherapy documentation reports.  Once the reports capture the appropriate 
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patients, a large observational study of aromatherapy effectiveness of similar design to the study 
conducted by Johnson and colleagues (2016) could be completed.  
The frequency and dose of opioid medication use in patients receiving lavender 
aromatherapy from EMR data is another outcome of interest for future scholarship.  Although 
decreases in pain intensity and opioid medication use in patients who receive aromatherapy were 
reported in the literature, these outcomes were not measured in this project.  One nurse PC 
anecdotally reported a patient decided to use the lavender aromatherapy during the day and 
opioids only at night to decrease pain to sleep.  The patient expressed effective pain management 
with this approach. 
The community hospital planned to engage nurse PCs in future implementation of TENS 
as another NPPMI.  The TENS implementation planning included the methodology of this EBP 
study: a logic model, the Iowa model strategy of nurse PCs, and electronic medical reports to 
measure documentation and prevalence of use. 
Conclusion 
The intervention of engaging change agents was effective in achieving implementation of 
nurse-directed lavender aromatherapy to improve pain management experience in adult patients 
on a surgical-orthopedic unit of a community hospital.  The surgical-orthopedic unit patient pain 
management experience percentile ranking increased from the 43rd percentile the quarter before 
implementation to the 78th percentile during the implementation period.  The Lunch & Learn 
presentations and Rounding for Results sessions impacted the extent of lavender aromatherapy 
adoption evidenced by the surgical-orthopedic unit patients comprising 61% of all community 
hospital patients screened for aromatherapy and 33% of the hospital’s lavender inhaler use.  Use 
of a logic model guided successful implementation.  The strategies of Lunch & Learn 
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presentations, Rounding for Results sessions, and nurse PC discussions were feasible.  The 
implementation of the nurse PC strategies of unit-huddles and peer coaching identified in the 
nurse PC discussions was limited to four of seven hospital units.  Adoption of the practice 
change was slower than anticipated and required additional rounds by the hospital CNS and 
nurse educators.  Utilization of EMR aromatherapy documentation reports provided insight into 
lavender aromatherapy use for all inpatients.  Rounding for Results observations provided 
insights for improvement of these EMR reports.  The logic model methodology, interventions of 
Lunch & Learn presentations, Rounding for Results sessions, and nurse PC-directed unit huddles 
and peer coaching were suitable for implementation of future practice changes. 
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Appendix A 
Non-Pharmacological Pain Management Intervention Frequency in an Audit of 65 Patient Records 
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Appendix B 
Completed Project Plan for Health System Product Pilot of Lavender Aromatherapy 
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Appendix C 
Health System Protocol for Lavender Aromatherapy for Pain Management 
Definitions 
• Clinical aromatherapy:  the use of oils that come from plants to improve how individuals feel 
physically and emotionally with outcomes that are measurable. It is different than aesthetic 
aromatherapy that is the use of oils for enjoyment.  
• Essential oils: plant derived oils that are extracted by distillation or extraction, which differs 
from fragrance oils that are synthetic and are often used in perfumes.   
• Direct inhalation: delivery of the aroma of the essential oil via an impregnated carrier such as 
an inhaler located near the patient. Direct inhalation differs from diffusion in which the 
essential oil is dispersed through a room. 
Target Population for Pain Management with Lavender Aromatherapy 
• The target population for lavender aromatherapy is adult patients, ages 18 and older, 
experiencing acute or chronic pain or who have anticipated procedural pain. This includes 
patients in inpatient, observation, emergency department or procedural settings.  
• Only patients who agree to use lavender aromatherapy should receive this intervention.  
• Although this product may be safely used in pediatric patients above the age of five, the 
initial implementation will be limited to adults. Inclusion of pediatric patients may be 
considered after successful implementation in the adult population.  
Product Selected by Health System Nursing Product Evaluation and Standardization 
Council (NPSEC) 
• Plant Extracts Aethereo®Sticks: an inhaler that the patient can hold and lasts for up to several 
months 
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Indications 
• Acute pain including post-operative pain and anticipated procedural pain.   
• Chronic pain, particularly neck and back pain.  
Contraindication 
• Patient allergy or intolerance to the lavender plant or lavender essential oil.  
Special Considerations 
• Avoid use of lavender aromatherapy when the patient is in contact with children under the 
age of five. This includes post-partum mothers while in contact with the newborn. The Plant 
Extracts Aethereo®Sticks inhaler should be closed when children under the age of five are in 
the room. 
• If visitors or associates who are in direct contact with the patient have intolerance to lavender 
aromatherapy, the Plant Extracts Aethereo®Sticks inhaler should be capped when those 
individuals are in the room. 
• In a semi-private room, if the patient’s roommate has intolerance to lavender aromatherapy, 
the Plant Extracts Aethereo®Sticks inhaler should be capped when the roommate is in the 
room. 
 Parameters for Lavender Aromatherapy 
• Only nurses who have received education about lavender aromatherapy may administer it. 
• A provider order is not required for lavender aromatherapy.  
• Only direct inhalation via the Aethereo®Sticks inhaler will be used as the mode of delivery. 
Diffusion will not be considered. 
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Patient Assessment and Provision of Lavender Aromatherapy 
• The nurse will ask the patient if he/she would like to use lavender aromatherapy and obtain 
patients’ verbal agreement prior to initiating its use.  
• The nurse may consider patients with decreased ability to smell for the intervention because 
these patients may still benefit from aromatherapy.  
• The nurse will assess the patient for history of intolerance to the lavender plant or essential 
oil.  
• In a semi-private room, the nurse will ask the patient’s roommate if she/he has intolerance to 
lavender aromatherapy. If the roommate is intolerant, the nurse may use judgment to select 
one of these actions: (a) advise the patient that the Plant Extracts Aethereo®Sticks inhaler 
should be capped when the roommate is in the room; (b) make arrangements, if feasible, for a 
room change to allow the aromatherapy without capping; or (c) stop the aromatherapy 
assessment.  
• The nurse will complete a pain assessment with a valid pain scale before and within 60 
minutes after initiation of lavender aromatherapy.  
• The nurse will review the patient and family education sheet for the product selected and 
instruct to the patient in a guided relaxation or deep breathing exercise during the initial use 
of the lavender aromatherapy. The education sheet may be printed from the aromatherapy 
assessment in MedConnect EMR system or from the StarPort intranet site. 
o The nurse will provide the aromatherapy with Aethereo®Sticks inhaler 
▪ Give the patient a lavender aromatherapy Aethereo®Sticks inhaler. 
▪ Instruct the patient to take off the top and hold it three or four inches from the nose 
and breathe in slowly.  
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▪ Assess the patient for any immediate intolerance to the Aethereo®Sticks inhaler. 
▪ Instruct the patient to do this as needed, but no more than four times an hour. 
▪ Instruct the patient to close the inhaler tightly after use.  
▪ Instruct the patient that the inhaler must be closed when near children under five. 
▪ Instruct the patient that the Aethereo®Sticks inhaler is intended for eternal use only. 
It is not to be placed in the mouth or nose. 
Disposal 
• The Aethereo®Sticks inhaler product should be capped and disposed of in a waste receptacle. 
Documentation 
The following elements should be documented in the electronic medical record:  
• Presence or absence of lavender contraindication/reaction. 
• Patient/family education provided. 
• Verbal agreement obtained. 
• Aromatherapy indication: acute pain, anticipated procedural pain, chronic pain. 
• Aromatherapy product administered: Aethereo®Sticks Lavender Inhalation. 
• Patient-reported aromatherapy frequency: More than once per hour, Once per hour, Every 2 
hours, Every 4 hours, Every 6 hours, Every 8 hours, Every 12 hours, Less than every 12 
hours. 





CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 75 
 
Safety and Adverse Reactions  
• Safety Information 
o Lavender aromatherapy is safe to use for most adult patients.1  
o There are no commonly reported side effects for direct inhalation of lavender 
essential oil.  
o Allina Health uses the Plant Extracts Aethereo®Sticks inhalers along with other 
products and reports no serious adverse events in over 60,000 aromatherapy 
applications in 13 hospitals and over 80 clinics and home care (J. Streeter, personal 
communication, May 24, 2018).  
• Management of Patient Intolerance 
o If a patient develops intolerance to the lavender aromatherapy, such as a headache or 
nausea, the nurse caring for the patient will immediately remove and discard the 
lavender aromatherapy product. The product should be capped and disposed in a 
closed waste receptacle outside of the patient room, preferably the soiled utility room.    
o The nurse will notify the physician or advanced practice clinician of the intolerance 
and note it in the patient’s electronic medical record. 
  
                                                          
1 Not regulated by the U.S. Food & Drug Administration (FDA). The FDA has not evaluated this 
statement. Aromatherapy is not intended to diagnose, treat, cure or prevent disease. 
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Appendix D 
Patient and Family Aromatherapy Education Document 
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Appendix E 
Nursing Education on Lavender Aromatherapy: PowerPoint Slides 
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Appendix F 
Lavender Aromatherapy Directions for Clinical Nurses 
Patients with acute or chronic pain may be candidates for aromatherapy. 
Product Name: Aethereo®Sticks Lavender Aromatherapy 
Inform patients about aromatherapy and its role in their overall treatment plan and goals. 
Inform patient that aromatherapy is not licensed by states or regulated by the FDA. 
Give Lavender Aromatherapy patent education sheet to the patient. 
Document lavender contraindications that patient or family provide. Do not administer. 
Obtain patient verbal agreement if no contraindications. 
Ascertain roommate intolerance to lavender direct accordingly (capping or room change). 
Perform initial pain assessment upon initiation and document in MedConnect. 
Patient Directions 
• Unscrew the top and hold the inhaler three or four inches from your nose.  
• Breathe in slowly. Repeat no more than four times an hour 
• Close tightly after use. 
• Store at room temperature.  
Reassess and document pain score one hour after use of lavender inhalation. 
If a patient develops intolerance to the lavender aromatherapy, such as a headache or 
nausea, the nurse caring for the patient will immediately remove and discard the lavender 
aromatherapy product. The product should be capped and disposed in a closed waste receptacle 
outside of the patient room, preferably the soiled utility room. 
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Appendix G 
Nurse-Directed Lavender Administration for Pain Management: 
An Overview for Physicians and Advanced Practice Clinicians 
Situation: Nurses will begin offering adult patients experiencing pain lavender aromatherapy by 
nasal inhalation, beginning Fall 2018. 
Background Information regarding Nurse-directed Lavender Aromatherapy: 
• Registered nurses will offer lavender aromatherapy nasal inhalers to adult patients 
experiencing pain. The inhaler contains a high-quality lavender essential oil. 
• A physician or advanced practice clinician (APC) order will not be required. 
• The nurse will assess the patient for intolerance to lavender then ask if the patient wants to 
use lavender aromatherapy. The patient will be instructed to hold the inhaler under the nose 
and take deep breaths to inhale the lavender aroma, up to four times an hour as needed. 
Nurses will document use in. In semi-private rooms, nurses will also assess roommates for 
intolerance before use can begin. 
• Lavender should not be used near children under 5 years of age. Patients will be instructed 
to cap the inhaler while children or others who may be intolerant are nearby. 
• There is moderate level of evidence that lavender inhalation improves acute pain 
management. 
o Randomized controlled clinical trials demonstrated statistically significant decreases in 
pain scores in the lavender inhalation group as compared to the controlled group 
(Bagheri-Nesami, Espahbodi, Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 
2015; Irmak Sapmaz et al., 2015; Karaman et al., 2016; Kim et al., 2007). Kim et al. 
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(2006) demonstrated statistically better patient satisfaction with pain management 
despite no statistically significant decreases in pain. 
o Kim et al. (2007) reported patients who inhaled lavender had statistically less opioid 
use than the control group (Kim et al., 2007). 
o Johnson et al. (2016) reported a mean decrease of 3 points on a 0-10 pain scale.  
• Patients in most of the health system hospitals have not reported satisfaction with pain 
management at the desired benchmark. Lavender aromatherapy is a nonpharmacological 
pain management intervention that aligns with Joint Commission standards. 
• Lavender inhalation is safe for most patients to use.2 
o Essential oils do not contain proteins that are associated with Type I hypersensitivity 
reactions. Like any other compound, it is possible for patients to develop IgG 
antibodies with exposure (J. Baraniuk, personal communication, May 23, 2018). 
However, this has not been commonly reported (Buckle, 2015). Use has not been 
associated with clinical worsening of asthma (Buckle, 2015). 
o Seven clinical trials reported no serious patient events (Bagheri-Nesami, Espahbodi, 
Nikkhah, Shorofi, & Charati, 2014; Heidari Gorji et al., 2015; Irmak Sapmaz et al., 
2015; Johnson et al., 2016; Karaman et al., 2016; Kim et al., 2006; Kim et al., 2007).  
o Two health systems, Allina Health and New York Presbyterian, reported no serious 
patient or associate safety events with use in multiple hospitals over multiple years 
(Joswiak et al., 2016; J. Seley, personal communication, May 30, 2018). 
                                                          
2 Not regulated by the U.S. Food & Drug Administration (FDA). The FDA has not evaluated this statement. 
Aromatherapy is not intended to diagnose, treat, cure or prevent disease. 
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Assessment: Nurse-directed lavender inhalation aromatherapy will be offered to patients 
experiencing pain.  
Request: Physicians and APCs become informed about this intervention. Physicians or APCs 
discuss concerns regarding use in specific patients with the clinical nurse caring for the patient. 
For additional information contact: Karen Mack, MS, MBA, APRN, CCNS, ACNP-BC, Clinical 
Practice Program Specialist, System Nursing. 
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Appendix H 
Supply Chain Launch Brief 
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Appendix I  
Aromatherapy Lunch & Learn Presentation Objectives and Agenda 
 
Learning outcomes: 
At the end of the Lunch & Learn session clinical nurses will: 
1. State the indications for aromatherapy. 
2. Identify the key steps in the aromatherapy appropriateness assessment. 
3. Explain how patients should use the lavender inhalers. 
4. Describe actions to take if a patient develops an intolerance to the lavender inhaler. 
 
Agenda: 
1. Introduction (5 minutes)  
Note: These questions will reinforce content provided in the aromatherapy computer-based 
module that some participants nurses will likely have completed before the session.  
Using a multiple-choice question and answer group participation session, clinical nurses will 
answer the following questions: 
a. What is lavender aromatherapy? 
i. A new paint color to enhance moods. 
ii. Non-pharmacological, intervention that uses lavender essential oil 
absorbed through the olfactory system used to manage pain and improve 
physical and emotional well-being. 
iii. A new product to improve the smell of the hospital linen. 
Answer ii is correct.       
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b. Which of the following does not a mechanism of action of lavender 
aromatherapy?  
i. Alters the perception at the sub-cortical and cortical pleasure memory 
centers of the brain. 
ii. Works via the nasal route to the limbic system via olfactory bulb or via the 
pulmonary route with inhalation of volatile compounds. 
iii. Causes the release cortisol.  
Answer iii is correct. It does not cause the release of cortisol but does 
affect neurotransmitter receptors for dopamine, seratonin and 
noradrenaline. 
c. True or false: Lavender aromatherapy requires a physician or advanced practice 
provider order. 
Answer “false” is correct. It is a nurse-directed intervention that requires 
assessment of patient intolerance 
d. The target population for lavender aromatherapy is: 
i. All patients having acute or chronic pain or may be having painful 
procedures. 
ii. Only patients 18 and older having acute or chronic pain or may be having 
painful procedures. 
iii. All patients because it may be helpful for sleep or anxiety. 
Answer ii is correct. Although lavender is helpful for sleep and anxiety, 
the hospital policy limits use to those patients 18 and older who are having 
pain. 
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e. When do the lavender inhalers expire? 
i. Seven days after opening. 
ii. Twenty-four hours day after opening. 
iii. Twelve months after opening. 
iv. Three months after opening. 
Answer iv is correct: Three months after opening. Discard any unopened 
inhaler that is more than 12 months old. 
2. Present content by reviewing two aromatherapy documents (5 minutes) 
a. Lavender Aromatherapy Directions for Clinical Nurses. See Appendix F. 
b. Aromatherapy Patient and Family Education document. See Appendix D. 
3. Learning assessment: (3 minutes)  
Using a group participation session, clinical nurses will answer the following questions: 
a. What are key points to highlight in educating patients? 
i. It can help patients manage pain, but it is not FDA regulated to treat pain.   
ii. To hold the inhaler three to four inches from the nose and breathe in 
slowly. 
iii. Close the inhaler when near children under 5 or anyone who says the 
smell makes them sick. 
b. Who can provide it to patients? 
i. Only registered nurses who have completed the computer-based module. 
c. What are the contraindications to lavender aromatherapy? 
i. Any patient-reported allergy or intolerance to lavender essential oil. 
d. What must a patient do before you provide the inhaler? 
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i. Verbally agree to use it. 
e. How long after the first lavender use do you reassess the patient’s pain intensity? 
i. Approximately one hour 





















CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 92 
 
Appendix J 
Nurse Pain Champion Meeting Aromatherapy Discussions 
The nurse pain champions will: 
• Identify nurse champion role domains that align with aromatherapy implementation. 
• Discuss aromatherapy indications, contraindications, patient education  
• Describe the four stages of the Iowa model of evidence-based practice (EBP) and how each 
relates to aromatherapy implementation using the Hospital Aromatherapy Implementation 
Action Plan. See Appendix P. 
• Determine two Iowa model EBP actions each nurse PC will take to foster implementation of 
aromatherapy on her/his nursing unit.  
• Review aromatherapy supply chain and electronic medical record report data at each 
meeting. 
• Identify implementation successes, barriers, best practice and barrier solutions. 
Meeting 1 Agenda (30 minutes) 
• Review: 
o Lavender Aromatherapy Directions for Clinical Nurses. See Appendix F. 
o Aromatherapy Patient and Family Education document. See Appendix D. 
• Review the Iowa model of EBP dissemination stages and strategies. See Appendix M. 
• Review the Hospital Aromatherapy Implementation Action Plan Iowa model strategies. See 
Appendix P. 
• Discuss what Iowa model strategies will be effective options the can implement for 
aromatherapy implementation and select two. 
CHANGE AGENT IMPACT ON PAIN THROUGH AROMATHERAPY 93 
 
• Develop two specific, measurable, attainable, relevant, time-bound SMART goals for 
aromatherapy to foster aromatherapy implementation with an action that each nurse PC will 
take in the next 30 days.  
• Review aromatherapy supply chain and electronic medical record report data. 
 
Meeting 2 Agenda (30 minutes) 
• Discuss the successes and any barriers noted regarding aromatherapy implementation on 
her/his unit. 
• Identify best practices and solution barriers from the discussion. 
• Report the two Iowa model EBP actions each nurse PC took to foster implementation of 
aromatherapy on her/his nursing unit.  
• Review aromatherapy supply chain and electronic medical record report data. 
• Discuss two actions each nurse PC will take to foster aromatherapy implementation in the 
next 30 days. This may include follow-up on pervious SMART goals or development of 
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Appendix K 
DNP Student Surgical-Orthopedic Unit Rounding for Results Form 
Week _______Date____________  
Nurse leader validates mentioning aromatherapy on leader rounds Yes No 
Aromatherapy par levels adequate Yes No 
Nurses who provide verbal intent to offer lavender: _______ 
Number of nurses interviewed on rounds: ________ 
Case  Lavender 
aromatherapy 
contraindication 




if no contraindication. 
Lavender aromatherapy 










1 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
2 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
3 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
4 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
5 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
6 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
7 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
8 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
9 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
10 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
11 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
12 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
13 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
14 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
15 Yes No N/A* Yes No N/A** Yes No N/A** Yes No N/A***  
* Pain is not present or anticipated and/or patient is excluded due to cognitive impairment, pregnancy, or prisoner status. 
** Contraindication to lavender present. 
*** Contraindication to lavender present or patient declined. 
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Appendix L 
Literature Review of Aromatherapy Experimental Trials with Lavender Aromatherapy as a Pain Management Intervention 
Citation  Research 
Question 

















the access site, is 
aromatherapy 
with lavender as 
compared to 
placebo 
The study was a 
randomized 
controlled clinical 
trial with an 
experimental 


























the AT and the CG 
after three sessions 
(p < .009). Both 
groups also had a 
significantly 
decreased pain 
score after three 
treatments as 
compared with 
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Citation  Research 
Question 




Sample size Results 
associated with 
decreased 
reported pain?  





In a population 











The study was a 
randomized 
controlled clinical 
trial with an 
experimental 

























the AT and the CG 
was noted at five, 
30, and 60-minute 
intervals post 
intervention as 
compared to the CG 
who received 
supplemental 
oxygen alone (p < 
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Citation  Research 
Question 














In a population 
of patients with 








The study was a 
double blinded 
placebo controlled 
clinical trial with 
an experimental 




was described but 
did not meet Jadad 
Aromatherapy 
with lavender 

















the AT and the CG 
was noted at 30 
minutes but not at 
10 minutes post 
intervention as 
compared to the CG 
who received 
placebo (p =.022 at 
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Citation  Research 
Question 













Jadad et al., 
1996). 
30 minutes, p = .152 
at 10 minutes). 
Karaman 
(2016) 







The study was a 
randomized 
controlled single-
blinded study with 
an experimental 
group (AT) and a 
Aromatherapy 
with lavender 
as compared to 
water placebo 
Self-reported pain 
and anxiety using the 
Visual Analog Scale 














reported pain and 
anxiety in the AT 
group as compared 
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Citation  Research 
Question 



















and due to 
drop-out for 
protocol 
issues, 51 were 
included in 
intervention 
and 50 in 
experimental 
group analysis.    
to the control group 
(p < .01 and p < 
.001 respectively). 




scores in the AT 
group as compared 
to the CG group (p 
< .003).  
Kim 
(2006) 
In a population 
of patients who 
have undergone 







using the Numeric 





and opioid analgesic 
use did not vary 
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Citation  Research 
Question 























group (AT) and a 
control group 




prior to surgery as 


















between the AT 
group and CG 
group and no p 
values were 
reported for either 





higher scores in the 
AT group as 
compared to the CG 
group (p < .05). 
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Citation  Research 
Question 











In a population 










The study was a 
randomized 
controlled clinical 
trial with an 
experimental 
group (AT) and a 
control group 
(CG). All enrolled 
patients received 
skin sensitivity 

















with a Numeric 
Rating Scale, 










and there was 
one drop-out 
for a protocol 
There was a 
statistically 
significant 
difference of lower 
opioid use amount 
and numbers of 
patients requiring 
opioids in the AT 
group as compared 
to the CG group (p 
< .04 and p < .007 
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Citation  Research 
Question 













analgesic use?  
surgery as 








recovery unit length 
of stay in minutes. 
issues in the 
AT group.    
respectively).  Body 
mass index and 
weight were 
significantly lower 
in the AT group (p< 
.05 for both). The 
AT groups sedation 
at discharge from 
the recovery unit 
was significantly 
lower than the 
control group 
(p<.05). There were 
no statistically 
significant 
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Citation  Research 
Question 




Sample size Results 
differences between 
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Appendix M 
Iowa Model Implementation Strategies 
 
Used/reprinted with permission from the University of Iowa Hospitals and Clinics, copyright 
2012. For permission to use or reproduce, please contact the University of Iowa Hospitals and 
Clinics at 319-384-9098. 
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Appendix N 
Aromatherapy Logic Model 
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Appendix O 
Weekly EMR System Aromatherapy Documentation Reports 
• Percent of patients with lavender aromatherapy contraindication screening documented.  
o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “Yes” or “No.” 
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients. 
• Percent of screened patients with lavender aromatherapy contraindication documented as 
“Yes.” 
o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “Yes.”  
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “Yes” or “No.” 
• Percent of screened patients with lavender aromatherapy contraindication documented as 
“No” and lavender aromatherapy inhaler offer documented as “Yes” or “No.”   
o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “No” and the Verbal 
Agreement field documented as “Yes” or “No.” 
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “No.” 
• Percent of screened patients with lavender aromatherapy contraindication documented as 
“No” and lavender aromatherapy inhaler offer documented as “Yes.”   
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o Numerator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “No” and the Verbal 
Agreement field documented as “Yes.” 
o Denominator: Number of adult (age 18 or older) surgical-orthopedic unit patients with 
Lavender Contraindication/Reaction field documented as “No.”
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Appendix P 
Community Hospital Aromatherapy Implementation Action Plan 




1.   Encouragement of nurses to complete 
an aromatherapy computer-based 
training module during the following 
interactions: nurse PC meetings, 
Lunch & Learn presentations, and 
Rounding for Results sessions. 
  
 Interest & Awareness 
Knowledge & 
Commitment 
Key Stakeholder Level 
By the end of the 
fourth week of DNP 
student Rounding for 
Results sessions. 
2.   Two nurse PC meeting discussions 
about how to promote aromatherapy in 
the practice setting.  
  
Interest & Awareness. 
Knowledge & 
Commitment, Action & 
Adoption; Integration & 
Sustainment  
Key Stakeholder Level, 
Organizational Level 
By the end of quarter 
three FY 2019. 
3.  Three Lunch & Learn aromatherapy 
presentations for surgical-orthopedic 
unit clinical nurses.   
Interest & Awareness 
Knowledge & 
Commitment  
Key Stakeholder Level 
By the end of the 
fourth week of DNP 
student Rounding for 
Results sessions.  
4.   Four DNP Rounding for Results 
sessions with clinical nurses on the 
surgical-orthopedic unit. 
Interest & Awareness, 
Knowledge & 
Commitment, Action & 
Adoption;  
Key Stakeholder Level 
By the end of quarter 
three FY 2019. 
5.   Development of reports including 
supply chain monthly lavender inhaler 
usage and EMR aromatherapy 
documentation report for nurse PCs to 
review at their meetings. 




By the end of the third 
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Appendix Q 















Worksheet 6                                                                                  Worksheet 7
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Appendix R 
Data Analysis Plan for Project Primary Clinical Question 
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain 
management experience in adult patients on a surgical-orthopedic unit of a community hospital?” 
Variable Type Measure 
Description 

































Lunch & Learns 
 





nurses and nursing 
associates 
1. Number of 
attendees per 
session and total 
2. Number of 
attendees by role 



























Number of patients 






















Ratio Mean, Range 
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Data Analysis Plan for Project Primary Clinical Question 
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain 
management experience in adult patients on a surgical-orthopedic unit of a community hospital?” 
Variable Type Measure 
Description 


































adult patient pain 
management 
experience for 
fiscal year (FY) 
2019 quarters 










how often did 
hospital staff talk 
with you about 
how to treat your 
pain?” will 



























Rank of unit and 
hospital percentage 
score as compared to 
Magnet hospitals in 
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Data Analysis Plan for Project Primary Clinical Question 
“Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain 
management experience in adult patients on a surgical-orthopedic unit of a community hospital?” 
Variable Type Measure 
Description 












in the NRC 
Picker database 
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Appendix S 
Data Analysis Plan for Project Aims 
Aim #1 To increase the surgical-orthopedic unit patient HCAHPS pain management experience score to equal or above the Magnet 
average of hospitals in the NRC Picker database by the end of the third quarter of FY 2019. 
Variable 
Type 









adult patient pain 
management experience 
quarterly percentage 
scores and Magnet 
hospital comparison 
percentiles for the 
question “During this 
hospital stay, how often 
did hospital staff talk 
with you about how to 











of patients answering 
the question “always” 
Denominator: 





Rank of percentage 
score as compared to 
Magnet hospitals in 
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Data Analysis Plan for Project Aims 
Aim #2 To achieve a consistent practice of 100 % of appropriate patients being offered lavender aromatherapy by the end of the 
third quarter of FY 2019. 
Variable 
Type 
Measure Description Data Source Population 
 



















The number of surgical-
orthopedic unit patients 
documented to have no 
contraindication to 
lavender aromatherapy 
and who received an 
offer of lavender 
aromatherapy reported 
on a weekly basis for the 
four weeks of the 
project and two weeks 
after the project based 
on weekly electronic 
medical record (EMR) 
documentation (each 



































The number of 
patients documented 
to have responded 





either “yes” or “no” 





The number of 
patients documented 
to have responded 
















































Data Analysis Plan for Project Aims 
Aim #2 To achieve a consistent practice of 100 % of appropriate patients being offered lavender aromatherapy by the end of the 
third quarter of FY 2019. 
Variable 
Type 
Measure Description Data Source Population 
 









The number of surgical-
orthopedic unit patients 
documented to have no 
contraindication to 
lavender aromatherapy 
and who received an 
offer of lavender 
aromatherapy reported 
on a weekly basis for the 
four weeks of the 
project based on 
Rounding for Results 
weekly observation 
sessions (each week = 
one rounding session of 
patient data on one day 





















and not cognitively 






with a documented 







and not cognitively 
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Appendix T 














































































































Ratio N by unit and by 
role 
No target for all 
clinicians 
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the number of 
lavender 
inhalers will be 
observed to be 
at par level for 












Number of yes 
responses, 




available in the 
2N and 2S 
supply bins at 

























of weeks that 
aromatherapy 
inhalers were 
available in the 




























of inhalers in 











inhalers in bins 






No target for 
weekly 
percentage 
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with the nurse 
manager or 


































Nominal Total percentage 
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Week 1: 20% 
Week 2: 40%  
Week 3: 60% 
Week 4: 80% 
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Week 1: 20% 
Week 2: 40% 
Week 3: 60% 









































of pain during 
admission, 
documentation 
of no lavender 









of pain during 
admission, 
documentation 
Week 1: 20% 
Week 2: 40% 
Week 3: 60% 
Week 4: 80% 
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agree or not 











had pain during 
the admission 






agree or not 















patients who  
had   
documentation 









patients who  
had   
documentation 
of no lavender 
contraindication 
Week 1: 20% 
Week 2: 40% 
Week 3: 60% 
Week 4: 80% 
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agree or not 














agree or not 
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by the end of the 
fourth week of 



































patients who  
No target was set 
for patient 
agreement to use 
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of no lavender 
aromatherapy 
contraindication 














had   
documentation 















“no” to lavender 
aromatherapy 
contraindication 
had   
documentation 






agree or not 



























































By the close of 
the third quarter 
of FY 2019, 
surgical-
orthopedic unit 
scores equal or 
above the 
average score of 
Magnet hospitals 
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how often did 
hospital staff 
talk with you 











Rank of unit and 
hospital 
percentage score 
as compared to 
Magnet 
























in the NRC 
Picker database 
 
By the close of 
the third quarter 
of FY 2019, 
surgical-
orthopedic unit 
scores will rank 
at the Magnet 
50th percentile in 




































































either “yes” or 





























100% of patients 
for the two 




five and six) 
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continued   
reported on a 
weekly basis for 
two weeks after 










































used on the 
surgical-
orthopedic unit 
each month.  
Ratio Monthly report 
of lavender 
inhaler use by 
the surgical-
orthopedic unit 
and the hospital 
overall will be 
compared with 
the March and 
April time 
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to use lavender 
aromatherapy 
inhalers weekly 
basis for two 
























patients who  
had   
documentation 


























patients who  
had   
documentation 






agree or not 




No target was set 
for patient 
agreement to use 
*Adults are patients 18 years of age and older. 
**Cognition was assessed by the nurse caring for the patient at the time of the Rounding for Results session. 
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Appendix U 
Project Primary Clinical Question Data Analysis 
 “Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain 













Sessions RN CNA US Total Attendee Attendee number per session range: 
5-9 
Attendee mean per session: 7 
Range among roles: 14 Registered 
Nurses, 6 Certified Nursing 
Assistants, and 1 Unit Secretary 
Yes  
1 5 2 0 7 
2 7 2 0 9 
3 2 2 1 5 
Total Per 
Role 








Sessions Patients Per Session Mean = 20 patients per session 





















Mean = 7.5 
Range = 7-8 
 
Note: Most pain champions and 
pain champion leaders attended both 
sessions.  
Yes 
1 4 4 8 
2 4 3 7 






Outcome: Met  
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Project Primary Clinical Question Data Analysis 
 “Was the strategy of change agents effective in achieving implementation of nurse-directed lavender aromatherapy to improve pain 
management experience in adult patients on a surgical-orthopedic unit of a community hospital?” 
After the intervention, the Surgical-orthopedic Unit exceeded the average score and 50th percentile of Magnet hospitals in the NRC 
Picker database for the question “During this hospital stay, how often did hospital staff talk with you about how to treat your pain?”  
Scores ranged from 52.2 in FY 19 Quarter 1 to 72.2 in FY 19 Quarter 3. 
Percentiles ranged from 12th in FY 19 Quarter 1 to 78th in FY 19 Quarter 3. 
Unit/Entity FY 19 Quarter 1 FY 19 Quarter 2 FY 19 Quarter 3 Total FY 19 Quarters 1-3 
Combined 
Positive PR n Size Positive PR n Size Positive PR n Size Positive PR n Size 
Surgical-orthopedic 
Unit 
52.2 12 46 63.0µ 43 27 72.2 78 36 61.5 40 109 
Hospital Overall 59.3 31 189 66.3 56 166 64.1 46 166 62.9 44 525 
NRC Picker Magnet 
Hospital Benchmark 
64.8 50  64.9 50  64.7 50  64.7 50  
µ= sample size below 30 patients and not adequate for statistical reliability as noted in the NRC Picker Database. 
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Appendix V 
Project Aims Data Analysis 
Aim #1 To increase the surgical-orthopedic unit patient HCAHPS pain management experience score to equal or above the Magnet 
average of hospitals in the NRC Picker database by the end of the third quarter of FY 2019 for the question “During this hospital 
stay, how often did hospital staff talk with you about how to treat your pain?” 
Outcome: Met  
After the intervention, the Surgical-orthopedic Unit exceeded the average score and 50th percentile of Magnet hospitals in the NRC 
Picker database.  
Scores ranged from 52.2 in FY 19 Quarter 1 to 72.2 in FY 19 Quarter 3. 
Percentiles ranged from 12th in FY 19 Quarter 1 to 78th in FY 19 Quarter 3. 
Unit/Entity FY 19 Quarter 1 FY 19 Quarter 2 FY 19 Quarter 3 Total FY 19 Quarters 1-3 
Combined 
Positive PR n 
Size 
Positive PR n Size Positive PR n Size Positive PR n Size 
Surgical-
orthopedic Unit 
52.2 12 46 63.0µ 43 27 72.2 78 36 61.5 40 109 
Hospital 
Overall 





64.8 50  64.9 50  64.7 50  64.7 50  
µ= sample size below 30 patients and not adequate for statistical reliability as noted in the NRC Picker Database. 
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Project Aims Data Analysis 
Aim #2 To achieve a consistent practice of 100 % of appropriate patients being offered lavender aromatherapy by the end of the 
third quarter of FY 2019. 
Aim #2a Outcome: Not Met 
Based on the weekly MedConnect EMR data below, 100% of surgical-orthopedic unit patients documented to have no 
contraindication to lavender aromatherapy received an offer of lavender aromatherapy reported on weeks 1, 2, 4, 5, and 6. The goal 
was not met on week 3. The range of percentages were 91.7% to 100% and the mean was 97.1%.  
Cerner MedConnect Electronic Medical Record Aromatherapy Data 
Population Surgical-Orthopedic Surgical Unit All Hospital Inpatients  

















































































Percent of patients with 
lavender aromatherapy 































































Percent of patients with 
documentation of 
































































*Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “Yes” or “No” and denominator is number of adult 
(age 18 or older) orthopedic surgical unit patients. 
** Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “Yes” and denominator is number of adult (age 18 
or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “Yes” or “No.”  
*** Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No” and the Verbal Agreement field documented 
as “Yes” or “No” and denominator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No.” 
**** Numerator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No” and the Verbal Agreement field 
documented as “Yes” and denominator is number of adult (age 18 or older) orthopedic surgical unit patients with Lavender Contraindication/Reaction field documented as “No.” 
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Project Aims Data Analysis 
Aim #2b Outcome: Not Met 
Based on Rounding for Results weekly observation sessions, 100% of surgical-orthopedic unit patients documented to have no 
contraindication to lavender aromatherapy received an offer of lavender aromatherapy on three of four weeks. The goal was not met 
on week 3. The range of percentages were 66.7% to 100% and the mean was 88.89%. 
Patients/ 
Outcomes 
Description Week 1 Week 2 Week 3 Week 4 Total 
Patients/ Records 
Observed 
Total Patients Rounded 21 19 18 20 78 
Patients Not Appropriate for Aromatherapy Screening Due 
to Cognitive Impairment or No Pain During Hospitalization 
9 7 12 12 40 
Patients with Documentation of Contraindication to 
Lavender 
0 0 0* 0 0 
Documentation 
Outcomes 
Goal 20% 40% 60% 80% N/A 
Appropriate patients** with lavender aromatherapy 











Goal 100% 100% 100% 100% 100% 


























Goal 100% 100% 100% 100% 100% 
Patients with documented agreement to use lavender 











*One patient reported intolerance to lavender, but documentation was not completed. 
** Patients without cognitive impairment and with reported pain during the hospital stay. 
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Appendix W 
Logic Model Outcomes Data Analysis 































orthopedic unit clinical 
nurses, and nurse PCs 
articulated: Lavender 
aromatherapy benefits, 
patient assessment protocol 
and patient education key 
points as indicated by 































1 E 30 
1 W 31 
2 E 19 
2 N/2S  26 (24 RN, 2 CNA) 
2 W 14 
Cardiac Cath Lab 21 
ICU/CCU 39 
Nursing Administration 5 




Resource Management & RN Float Pool 43 
Rehab-Stroke Center 2 
Women's Services 46 
Total 329 
Community Hospital Aromatherapy SiTEL Completion by Role  
Role N 
Clinical Nurses (Direct Care) 225 
Certified Nursing Assistants 32 
Nurse Leaders 18 
Technicians 12 
Non-Direct Care Nurses 11 
Unit Secretary 10 
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Logic Model Outcomes Data Analysis 























Other (Center Hall Coordinator/OR 
Transport) 
5 










clinical nurses, including 
nurse PCs, articulated intent 
to offer lavender inhalers to 
patients at each Rounding 
for Results session  
Nurses who 
provide verbal 
intent to offer 
lavender 





met three out 
of four 
weeks) 




















At each Rounding for 
Results session, surgical-
orthopedic unit nurses’ 
skills to appropriately use 
and teach patients to use 
lavender inhalers was 
evaluated by observation of 








correct use of 
lavender inhaler 
Week Total Target=100% 
Outcome= 
Not met  
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Logic Model Outcomes Data Analysis 








At each Rounding for 
Results session, the par 
levels for lavender inhalers 
that were established by the 
surgical-orthopedic unit 
nurse leaders were 
compared with the adequacy 
and number of lavender 
inhalers observed  









1 2 3 4 
Inhalers Available in 
Bin (YES, NO) 
YES YES YES YES 4/4 YES 






1 2 3 4 
Inhaler Count North 
Supply Room 
6 10 6 8 30 
Inhaler Par North 
Supply Room 
5 10 10 10 35 
% Inhaler Count to 
Par North Supply 
Room 
120% 100% 60% 80% 86% 
Inhaler Count 
South Supply Room 
3 9 6 8 26 
Inhaler Par South 
Supply Room 
5 10 10 10 35 
% Inhaler Count to 
Par South Supply 
Room 
60% 90% 60% 80% 74% 
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Logic Model Outcomes Data Analysis 








At each Rounding for 
Results session, orthopedic 
surgical unit nurse leaders, 
including the nurse manager 
or charge nurse on duty, 
validated lavender inhalers 
were mentioned during their 
nurse leader rounds with 
patients 





1 2 3 4 
Nurse leader validates 
mentioning 





YES YES 4/4 YES 
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Logic Model Outcomes Data Analysis 















Week Total Target= 
Week 1: 20%  
Week 2: 40%  
Week 3: 60%  
Week 4: 80% 
Outcome= 
Not met on 
any of the 
four weeks 
1 2 3 4 N/A 
Based on Rounding for 
Results observation: 
Percent of appropriate 
























Based on weekly 
MedConnect EMR 
reports: Percent of 





























Week 1: 20%  
Week 2: 40%  
Week 3: 60%  
Week 4: 80% 
Outcome= 
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Logic Model Outcomes Data Analysis 










patients with documentation 






Week Total Target= 
Week 1: 20%  
Week 2: 40%  
Week 3: 60%  
Week 4: 80% 
Outcome= 
Met on all 
four weeks 
1 2 3 4 
Based on Rounding for 
Results observation: 
Lavender aromatherapy 
offer and education 
documented if no 





















Based on Weekly 
MedConnect EMR 
reports: Percent of 
screened patients with 
lavender aromatherapy 
contraindication 
documented as “No” 
and lavender 
aromatherapy inhaler 
offer documented as 




























correct use of the lavender 
inhalers during Rounding 
for Results sessions 
 
Patient Use of Lavender 
Inhaler  





1 2 3 4 
Based on Rounding for 
Results observation: 
Patient demonstrates 
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Logic Model Outcomes Data Analysis 








Percent of screened 
surgical-orthopedic unit 
patients with documentation 
of no lavender 
aromatherapy 
contraindication who agreed 
to use lavender 
aromatherapy inhaler. 
Patient Agreement to 
Use Lavender Inhalers 
Week Total No target was 
set for patient 
agreement to 
use 1 2 3 4 
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Logic Model Outcomes Data Analysis 














page 2  
 
Surgical-orthopedic unit 
adult patient pain 
management experience for 
fiscal year (FY) 2019 
quarters one through three 
quarterly percentage scores 
and Magnet hospital 
comparison percentiles for 
the question “During this 
hospital stay, how often did 
hospital staff talk with you 
about how to treat your 
pain?” 
 FY 2019 Quarter Target =  
By the close 
of the third 


















1 2 3 1-3 Combined 
Magnet Average 64.8 64.9 64.7 64.7 
Number of Patient 
Responses 
46 27 36 109 
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Logic Model Outcomes Data Analysis 











pages 3 and 4 
The number of surgical-
orthopedic unit patients 
documented to have no 
contraindication to lavender 
aromatherapy and who 
received an offer of 
lavender aromatherapy 
reported on a weekly basis 





Week Mean of 
Weeks 
5 & 6 
Target= 100% 
of patients in 








Target = Met 
5 6 
Based on Weekly 
MedConnect EMR 
reports: Percent of 
surgical-orthopedic unit 
screened patients with 
lavender aromatherapy 
contraindication 
documented as “No” 
and lavender 
aromatherapy inhaler 
offer documented as 










Based on hospital supply 
chain, the number of 
lavender inhalers consumed 
on the surgical-orthopedic 















Feb. March April 
Surgical-orthopedic 
Unit  
69 75 79 223 
All Hospital Inpatient 
Units (nine units 
including surgical-
orthopedic unit) 
207 212 250 669 
Surgical Unit Percent 
of Overall Lavender 
Inhaler Consumption   
33% 35% 32% 33% 
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Logic Model Outcomes Data Analysis 








patients with documentation 
of no contraindication and 
agreement to use lavender 
aromatherapy inhalers 
weekly basis for two weeks 











Patient Agreement to 
Use Lavender Inhalers 
Week Mean of 
Weeks 
5 & 6 
No target was 




Based on weekly 
MedConnect EMR 
reports: Based on 
Weekly MedConnect 
EMR reports: Percent 
of surgical-orthopedic 




documented as “No” 
and lavender 
aromatherapy inhaler 






















































Percentage of Surgical-Orthopedic Unit vs. All Inpatients with 
Documentation of Assessment for Contraindication to Aromatherapy 
Surgical Orthopedic Surgical Unit
All Inpatient Units
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